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ABSTRACT 
MCL-1 is an essential BCL-2 family member that promotes the survival of 
multiple cellular lineages, but its role in cardiac muscle has remained unclear. Here, we 
have demonstrated that cardiac-specific ablation of Mcl-1 results in a rapidly fatal, dilated 
cardiomyopathy preceded by loss of myofibrils and cardiac contractility, abnormal 
mitochondria ultrastructure, defective mitochondrial respiration, and impaired autophagy. 
Genetic ablation of both pro-apoptotic effectors (Bax and Bak) could largely rescue the 
lethality and impaired cardiac function induced by Mcl-1 deletion. However, Mcl-1-, 
Bax-, and Bak-deficient hearts still revealed mitochondrial ultrastructural abnormalities 
and displayed deficient mitochondrial respiration, and are hypersensitive to chronic 
isoproterenol challenge. Together, these studies indicate that MCL-1 functions beyond 
merely blocking cardiomyocyte death and suggest that in myocardium, MCL-1 also 
facilitates normal mitochondrial function. These findings are important, as 
overexpression MCL-1 in the heart could be a potential strategy to overcome cardiac 
injury and promote efficient mitochondrial function and would be beneficial to human 
health. Of equal importance, specific MCL-1-inhibiting therapeutics that has been 
proposed to treat cancer may result in unexpected cardiac toxicity; it may be necessary to 
take this possible side effect into account during MCL-1 inhibitor development. 
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1CHAPTER 1.   INTRODUCTION 
BCL-2 Family and Apoptosis 
Apoptosis is an essential part of the life cycle for many organisms, and a 
fundamental mechanism for homeostasis of tissues. Dysfunction of apoptosis leads to a 
variety of human pathologies including cancer, neurodegenerative, and autoimmune 
diseases (Cory and Adams 2002). Apoptosis is initiated when death stimuli trigger multi-
protein complexes that recruit and activate initiator caspases. There are two cell death 
pathways requiring the activation of initiator caspases (by multi-protein complexes), 
extrinsic and intrinsic apoptosis pathway (Munoz-Pinedo 2012) (Figure 1-1).  
In the extrinsic apoptosis pathway, death stimuli interact with death receptors on 
the surface of the cell.  The death receptors contain an intracellular death domain that 
recruits and activates initiator Caspase-8. Once activated, Caspase-8 activates effector 
caspases, such as Caspase-3, which cleave a number of cellular components to induce 
cell death (Hengartner 2000) (Figure 1-1).  In many cell types, the extrinsic pathway for 
cell death does not involve BCL-2 family members or mitochondrial outer membrane 
permeabilization (MOMP) to amplify the death signal. 
On the other hand, the intrinsic apoptosis pathway is regulated by BCL-2 family 
members on the mitochondria. BCL-2 family members can be divided into two groups 
according to their function: pro-apoptotic members and anti-apoptotic members. BCL-2 
family members share homology within four conserved amphipathic alpha-helical 
segments called BCL-2 homology domains (BH) (Youle and Strasser 2008). The anti-
apoptotic members (such as BCL-2, BCL-XL, MCL-1, A1 and BCL-w) possess multiple 
BH domains and form a hydrophobic pocket that allows these members to interact with 
the BH3 domain of other pro-apoptotic family members to perform the anti-apoptotic 
function. The pro-apoptotic members can be further divided into two subgroups 
depending on the number of BH domains; multi-domain pro-apoptotic effectors (such as 
BAX, BAK and BOK) and BH3 only pro-apoptotic members (such as BID, BAD, BIM, 
BIK, NOXA, PUMA, etc.) (Cheng et al. 2001; Opferman and Korsmeyer 2003; Petros et 
al. 2004) (Figure 1-2). BH3 only members reside upstream of the intrinsic apoptosis 
pathway, and can be activated by different death stimuli to promote the activation and 
oligomerization of BAX and BAK. BAX and BAK oligomers permeablize the outer 
mitochondrial membrane (OMM) and facilitate the release of several apoptogenic 
proteins including cytochrome c. Cytochrome c then binds to apoptotic protease-
activating factor-1 (APAF-1) to induce a conformational change, so that APAF-1 can 
recruit initiator Caspase-9. APAF-1 bound Caspase-9 can then activate itself through 
dimerization. The activated Caspase-9 then activates effector caspases, which cleave a 
myriad of intracellular targets, to induce cell death (Gross et al. 1999) (Figure 1-1).
  
2Figure 1-1. Scheme depicting intrinsic and extrinsic pathways of apoptosis 
Apoptosis can be induced by cell surface receptors, such as Fas and tumor necrosis factor 
receptor-1 (TNFR1) (extrinsic pathway, right), or by various genotoxic agents, metabolic 
insults or transcriptional cues (intrinsic pathway, left). The intrinsic pathway starts with 
BH3-only protein induction or post-translational activation, which results in the 
inactivation of some BCL-2 family members. This relieves inhibition of BAX and BAK 
activation, which in turn promotes apoptosis. Some BH3-only proteins, such as BIM and 
PUMA, may also be able to activate BAX and/or BAK (as shown by the dotted line). 
Once activated, BAX and BAK promote cytochrome c release and mitochondrial 
fragmentation, which leads to the activation of APAF1 into an apoptosome and activates 
Caspase-9 to activate Caspase-3. Caspases in turn cleave a series of substrates, activate 
DNases and orchestrate the demolition of the cell. The extrinsic pathway can bypass the 
mitochondrial step and activate caspase-8 directly, which leads to Caspase-3 activation 
and cell demolition. The BCL-2 family regulates the intrinsic pathway and can modulate 
the extrinsic pathway when cleavage of BID communicates between the two pathways. 
Reprinted with permission from Macmillan Publishers Ltd: Youle RJ, Strasser A. 2008. 
The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell 
Biol 9: 47-59.  
3Figure 1-2. The BCL-2 family 
The BCL-2 family compromises pro-apoptotic and anti-apoptotic members. BCL-2 
family members share homology within four conserved ?-helical segments, called BH 
domains. The anti-apoptotic BCL-2 family members (BCL-2, BCL-XL, BCL-w and A1) 
possess multiple BH domains, of which the BH1-BH3 domains form a hydrophobic 
pocket capable of binding the BH3 domain of the other pro-apoptotic family members. 
Boo/Diva is a mouse BCL-2 homology that is highly expressed in the ovary, but only 
weakly in other tissues. NR13 is the avian cell death antagonist shares homology with 
Boo/Diva. The pro-apoptotic family members can be subdivided into two groups 
according to the number of BH domains they possess. The multi-domain pro-apoptotic 
members (BAX, BAK and BOK) possess the BH1, BH2 and BH3 domains. In contrast, 
the BH3-only members contain only the BH3 minimal death domain. Reprinted with 
permission from Macmillan Publishers Ltd: Opferman JT, Korsmeyer SJ. 2003. 
Apoptosis in the development and maintenance of the immune system. Nature 
Immunology 4: 410-415. 
4
5Dual Functions of MCL-1 
MCL-1, the induced myeloid leukemia cell differentiation protein, is an anti-
apoptotic BCL-2 family member and was initially identified as an immediate-early gene 
(Myeloid cell leukemia sequence, Mcl-1) expressed during TPA-induced differentiation 
of ML-1 myeloid leukemia cells (Kozopas et al. 1993). Sequence analysis reveals that the 
carboxy-terminus of MCL-1 shares homology with other pro-apoptotic BCL-2 family 
members, containing three putative BH domains (BH2, BH1 and BH3), which confer the 
ability to interact with other family members, and a hydrophobic transmembrane domain 
at the extreme carboxy-terminus (Kozopas et al. 1993). However, the amino-terminus of 
MCL-1 is poorly conserved as it is much longer than other pro-apoptotic BCL-2 family 
members and is intrinsically unstructured and excluded from structural study (Day et al. 
2005). Truncation of either the carboxy- or amino-terminus of MCL-1 does not abolish 
its ability to bind pro-apoptotic BCL-2 family members (Day et al. 2005).  
A variety of growth factors and cytokines have been revealed to regulate MCL-1 
expression. Interleukin-7 (IL-7) stimulation could upregulate MCL-1 expression in both 
mature lymphocytes and immature progenitors (Opferman et al. 2003; Dzhagalov et al. 
2008; Dunkle et al. 2011). And the Mcl-1 mRNA level is also induced in hematopoietic 
stem cells in response to stem cell factor (SCF) and IL-6 (Huang et al. 2000; Opferman et 
al. 2005). Granulocyte-macropahge colony-stimulating factor (GM-CSF) and IL-3 could 
enhance MCL-1 expression in cell lines through PI3K/Akt signaling pathway (Wang et 
al. 1999b). And conversely, IL-3 withdraw in BAF/3 cells leads to a decrease in MCL-1 
expression (Maurer et al. 2006). In addition, Mcl-1 mRNA translation is regulated by 
mTORC1 pathway (Mills et al. 2008). Therefore, MCL-1 can be regulated at both 
transcriptional and translational levels. 
In addition, post-translational modification can also regulate MCL-1 expression. 
MCL-1 possesses multiple potential phosphorylation sites, and their modification may 
have different effects on MCL-1 anti-apoptotic function. For example, cyclin dependent 
kinase 1 (CDK1), CDK2 and c-Jun NH(2)-terminal kinase (JNK)-mediated 
phosphorylation of Ser64 enhances the interaction between MCL-1 and pro-apoptotic 
proteins to facilities its pro-survival function (Kobayashi et al. 2007). Phosphorylation of 
Thr92 in conjunction with Thr163 by extracellular signal-regulated kinase-1 (ERK-1) 
stabilizes MCL-1 and promotes survival (Ding et al. 2008). In contrast, phosphorylation 
of Ser155 in conjunction with Ser159 and Thr163 by glycogen synthase kinase-3 (GSK3) 
destabilizes MCL-1 and impairs its anti-apoptotic function (Ding et al. 2007). 
The amino-terminus of MCL-1 contains two PEST sequences that are typically 
present in short lived proteins (Kozopas et al. 1993). And MCL-1 does have a short half-
life that distinguishes it from other BCL-2 family members (Nijhawan et al. 2003). MCL-
1 undergoes both ubiquitin-dependent and -independent degradation (Stewart et al. 2010). 
Three E3 ubiquitin-ligases have been reported to promote the ubiquitinylation of MCL-1, 
including MCL-1 ubiquitin ligase E3 (MULE), a HECT-domain containing E3 (Zhong et 
al. 2005), as well as ß-TrCP and FBW7, the SKP1-cullin-1-F-box (SCF) complex E3 
ligases in a phosphorylation dependent manner (Ding et al. 2007; Inuzuka et al. 2011). 
6Moreover, MCL-1 degradation is inhibited by the USP9X deubiquitinase, stabilizing 
MCL-1 protein expression and leading to apoptotic resistance (Schwickart et al. 2010).  
  
MCL-1 is localized to various intracellular membranes, including the 
mitochondria (Yang et al. 1995), the endoplasmic reticulum (ER) (Germain and Duronio 
2007) and the nuclear envelope (Fujise et al. 2000; Jamil et al. 2005). The predominant 
mitochondrial localization of MCL-1 is necessary for its anti-apoptotic function, while it 
has been reported that nuclear localized MCL-1 interacts with CDK1 and proliferating 
cell nuclear antigen (PCNA) to modulate cell cycle progression. 
Anti-apoptotic MCL-1 and Cell Survival 
As an anti-apoptotic protein, the classical function of MCL-1 is to promote 
survival via interacting with the pro-apoptotic family members. Quantitative assessment 
of the affinity between pro-survival BCL-2 proteins and the BH3 domains of their pro-
apoptotic partners vary enormously and MCL-1 selectively binds to specific pro-
apoptotic family members (Chen et al. 2005b). While all anti-apoptotic proteins can 
interact with BH3-only proteins including BIM, PUMA and tBID, MCL-1 and A1 are 
engaged in the interaction with NOXA. In contrast to BCL-2, BCL-XL and BCL-W, 
MCL-1 does not interact with BAD (Chen et al. 2005b). Moreover, the multidomian pro-
apoptotic protein BAK can interact with MCL-1 and BCL-XL, but not BCL-2 or A1 
(Willis et al. 2005). MCL-1 also interacts with BAX (Sedlak et al. 1995) and can protect 
myeloid progenitors against apoptosis in response to various death stimuli including 
chemotherapeutic drug, calcium ionophore, UV irradiation, and growth factor withdrawal 
(Zhou et al. 1997). 
The role of anti-apoptotic BCL-2 family members in regulating homeostasis 
during various stages of hematopoiesis has been revealed via loss of function studies 
(Figure 1-3). Bcl-2 deficient mice are viable at birth but die within a few months and 
exhibit renal failure and apoptosis of lymphocytes (Veis et al. 1993). Bcl-XL deficient 
mice exhibit lethality at embryonic day (E) 13 and excessive death of neurons and 
immature lymphocytes (Motoyama et al. 1995). Bcl-w and A1 deficient mice are viable 
but display defects in spermatogenesis and accelerated neutrophil apoptosis respectively 
(Hamasaki et al. 1998; Print et al. 1998).  
Gene-ablation studies have demonstrated that MCL-1 has distinct roles that are 
remarkably divergent from other pro-apoptotic BCL-2 family members. Mcl-1 deficient 
mice exhibit peri-implantation embryonic lethality (E3.5-4) (Rinkenberger et al. 2000). 
Conditional knockout studies further indicate that MCL-1 is essential for multiple stages 
of hematopoiesis and lymphopoiesis (Figure 1-3). Conditional deletion of Mcl-1 in the 
early stage of T lymphocyte differentiation by using lymphocyte-specific protein tyrosine 
kinase-Cre (Lck-Cre) results in no viable and mature Mcl-1-deleted T cell. Deletion of 
Mcl-1 during early B lymphocyte development by using CD19-Cre increases apoptosis at 
the pro-B stage. Deletion in mature lymphocytes results in apoptosis, suggesting that  
7Figure 1-3. Role of anti-apoptotic regulators during hematopoiesis 
All blood cell lineages arise from a hematopoietic stem cell (HSC) that is capable of self-
renewal and has an indefinite life-span. HSCs give rise to multi-potent progenitors 
(MPPs) which still retain the ability to give rise to all blood cell lineages, but lack long-
term self-renewal capacity. MPPs can produce two progenitors, common myeloid 
progenitors (CMPs) and common lymphoid progenitors (CLPs). CLPs can produce the 
lymphoid lineages (B, T, and perhaps NK cells). CMPs produce at least two other 
oligopotent progenitor populations, the megakaryocyte erythroid progenitor (MEP) that 
produce red blood cells (erythrocytes) and megakaryocytes (generates platelets) and the 
granulocyte monocyte progenitor (GMP) that produces granulocytes (neutrophils) and 
monocytes (macrophages). Listed beside each differentiation step or progenitor 
population are the known anti-apoptotic regulators that promote the survival of the given 
population. Anti-apoptotic MCL-1 has multiple checkpoints as it has been illustrated to 
be critical for the survival of several multipotent and oligopotent progenitor populations 
(HSC, CMP, CLP, and GMP) and has been shown to be critical for the differentiation of 
granulocytes, but interestingly not the monocyte lineage. A1-a, a murine ortholog of 
BFL-1, and other A1 isoforms have also been shown to play an important role in 
promoting neutrophil survival in response to stress, but are not absolutely required for 
development, but primarily effect mature cell survival (indicated by open arrowhead). A1 
isoforms also play a role, but are not essential in lymphoid development. In the erythroid 
lineage, it appears that anti-apoptotic BCL-XL is the essential survival molecule, but 
unpublished data indicates that MCL-1 may also play an essential role during early 
differentiation. In the megakaryocytic lineage it appears that while neither MCL-1 nor 
BCL-XL is solely responsible for survival, the two pro-survival molecules appear to have 
overlapping functions (indicated by open arrowheads) in promoting megakaryocyte 
survival. Reprinted with permission from Elsevier Ltd: Perciavalle RM, Opferman JT. 
2013. Delving deeper: MCL-1's contributions to normal and cancer biology. Trends in 
cell biology 23: 22-29.  
8MCL-1 is required for the development and maintenance of lymphocytes (Opferman et 
al. 2003). 
Furthermore, MCL-1 also plays an indispensable role in early stage of 
hematopoiesis (Figure 1-3), supported by the observation that conditional deletion of 
Mcl-1 in early hematopoietic progenitors results in rapid hematopoietic failure. The 
earliest populations lost are the hematopoietic stem cells (HSCs), common myeloid 
progenitors (CMPs), and common lymphoid progenitors (CLPs) (Opferman et al. 2005). 
MCL-1 plays a selective role in myelopoiesis as MCL-1 is required for the development 
of mature neutrophils from granulocyte precursors. Whereas deletion of Mcl-1 in the 
myeloid lineage does not block the maturation of macrophages, it is important for 
survival during macrophage effector function (Steimer et al. 2009). Moreover, MCL-1 is 
necessary for the survival of nature killer (NK) cells, as specific deletion of Mcl-1 in NK 
cells results in absolute loss of NK cells from all tissues due to apoptosis (Sathe et al. 
2014). 
In addition to its pivotal role at different stages of hematopoiesis, MCL-1 is also 
required for cortical neurogenesis and the survival of neurons after DNA damage. 
Conditional deletion of Mcl-1 in the forebrain leads to embryonic lethality at day 15 and 
deletion of Mcl-1 earlier in the central nerve system leads to lethality at E12.5 (Arbour et 
al. 2008). 
In a human, MCL-1 is expressed in epithelial cells of the skin, gastrointestinal 
tract, and pulmonary tissues, in cardiac and skeletal muscle, hematopoietic cells, 
lymphocytes, uterus, adrenal cortex, sympathetic ganglia, pancreatic islets, and 
hepatocytes (Krajewski et al. 1995). Besides the blood cells, the function of MCL-1 in 
many other cell types still remains to be established.  
MCL-1 and Mitochondrial Physiology 
MCL-1 protein appears as a doublet (40 kD and 36 kD) or sometimes a triplet (40 
kD, 38 kD and 36 kD) as detected by immunoblot in many cell types. Several hypotheses 
have been implied to explain the origin of those bands. Phosphorylation of MCL-1 has 
been proposed to generate the 40 kD isoform, but phosphatase treatment does not abolish 
the formation of this band (Perciavalle et al. 2012). Non-canonical translation has been 
reported to produce the 36 kD species of MCL-1 (Warr and Shore 2008), however, 
removing the ATG start codon of MCL-1 only produces a 31 kD truncated protein from a 
downstream ATG codon instead (Perciavalle et al. 2012). Moreover, non-canonical 
messenger RNA splicing has been proposed to give rise to the 36 kD isoform (Kojima et 
al. 2010), but ablation of the putative splice donor and acceptor does not abrogate the 
doublet or triplet formation (Perciavalle et al. 2012). Recently, proteolytic cleavage has 
been demonstrated to contribute to the generation of different MCL-1 species (Huang and 
Yang-Yen 2010; Perciavalle et al. 2012). Indeed, amino-terminal Edman sequencing of 
immunoprecipitated MCL-1 discovered two cleavage sites: the first between MCL-1’s 
isoleucine-10 and glycine-11and another between leucine-33 and valine-34. As a result, 
9proteolysis at the amino-terminus of MCL-1 produces three MCL-1 species with different 
molecular weight: full-length (40 kD), cleaved at isoleucine-10 (38 kD), and cleaved at 
leucine-33 (36 kD) (Perciavalle et al. 2012). 
Sub-mitochondrial Localization of MCL-1. Further analysis revealed that the 
various forms of MCL-1 exhibit different mitochondrial sub-localizations; the slowly 
migrating forms of MCL-1 (40 kD and 38 kD) reside on the outer leaflet of the OMM, 
whereas the 36 kD form of MCL-1 is associated with the inner mitochondrial membrane 
(IMM) and confined within the mitochondrial matrix in a manner dependent upon the 
translocases of the outer and inner mitochondrial membrane (TOM and TIM complexes) 
(Perciavalle et al. 2012). Similarly, another study has also reported that the truncated 
form of MCL-1 resides in the mitochondrial matrix and the matrix processing peptidase 
(MPP) is responsible for the cleavage of a mitochondrial targeting sequence (MTS) at the 
amino-terminus of MCL-1, suggesting that MCL-1 is cleaved during import into the 
mitochondria (Huang and Yang-Yen 2010). 
MCL-1 Promotes Mitochondrial Physiology. The Opferman laboratory has 
reported that different forms of MCL-1 reside in distinct mitochondrial locations and 
exhibit separable functions. The OMM localized form of MCL-1 possesses the classical 
anti-apoptotic activity where it antagonizes BAX and BAK activation to maintain 
mitochondrial integrity. In contrast, the matrix-localized form of MCL-1 is unable to 
inhibit apoptosis, but is necessary for maintaining IMM structure, regulating fusion and 
promoting the assembly of ATP synthase oligomers. As shown in SV40-transformed 
Mcl-1flox/flox Rosa-ERCreT2 murine embryonic fibroblast (MEFs), deletion of Mcl-1 by 
tamoxifen induction results in decreased ATP production, oxygen consumption, IMM 
fusion, mitochondrial DNA (mtDNA) level, increased reactive oxygen species (ROS), a 
loss of electron transport chain (ETC) supercomplex, and a loss of normal mitochondrial 
cristae structure, which can only be rescued by putting back matrix localized form of 
MCL-1 (Perciavalle et al. 2012). Thus, besides the classical anti-apoptotic function, 
MCL-1 is necessary for facilitating mitochondrial homeostasis and supporting 
mitochondrial bioenergetics function in the model cell line (Figure 1-4).
How MCL-1 promotes mitochondrial physiology and what is the primary 
deficiency due to its ablation remains elusive. Since cells lacking matrix-localized MCL-
1 exhibit reduced enzymatic activity of ETC complexes (Perciavalle et al. 2012), it is 
possible that MCL-1 may directly modulate the function of one or more of the ETC 
components. As a result, the mitochondrial oxidative phosphorylation (OXPHOS) is 
diminished and ATP production decreased, leading to the mitochondrial morphological 
changes, as the morphology of mitochondria is tightly related to the bioenergetic status 
(Mannella 2006).    
Additionally, MCL-1 may regulate IMM structure by facilitating the dimerization 
and oligomerizaton of F1F0-ATP synthase (Perciavalle et al. 2012). ATP synthase is  
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Figure 1-4. Model for MCL-1’s potential functions in mitochondria 
MCL-1 possesses multiple functions in mitochondria. (a) On the outer mitochondrial 
membrane (OMM), MCL-1 functions like other antiapoptotic BCL-2 family members 
where it acts to prevent the activation of BAX and BAK to prevent cell death. MCL-1 
can directly bind BH3-only family members, such as BIM, sequestering them away from 
the proapoptotic effectors BAX and BAK. Alternatively, MCL-1 may directly bind BAX 
and BAK and maintain them in an inactive conformation. (b) During mitochondrial 
importation, the full-length MCL-1 is proteolytically truncated at its amino terminus. The 
truncated, matrix-localized MCL-1 resides within the inner mitochondrial membrane 
(IMM), where it functions to maintain mitochondrial cristae ultrastructure and promotes 
the assembly of the electron transport chain (ETC) complexes into higher-order 
assemblies known as supercomplexes (SCs). The assembly into supercomplexes has been 
shown to facilitate electron transport efficiency and reduce the production of deleterious 
reactive oxygen species. Additionally, matrix-localized MCL-1 facilitates the higher-
order assembly of the ATP synthase complexes into dimers and oligomers. Proper 
assembly of oligomeric ATP synthase has been implicated as being an important 
determinant of inner membrane cristae structure. Genetic ablation of Mcl-1 results in 
defects in both supercomplex and ATP synthase oligomer assembly. Whether MCL-1 
acts directly or indirectly to facilitate these macromolecular assemblies of the electron 
transport supercomplexes or ATP synthase oligomers remains unclear. Reprinted with 
permission from Elsevier Ltd: Perciavalle RM, Opferman JT. 2013. Delving deeper: 
MCL-1's contributions to normal and cancer biology. Trends in cell biology 23: 22-29. 
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composed of a soluble catalytic unit (F1) in the mitochondrial matrix, and a membrane-
bound unit (F0) anchoring the enzyme in the IMM and mediating the flow of protons 
through the membrane. The ATP synthase dimers and oligomers are thought to be 
responsible for the generation of cristae and could facilitate ATP production (Paumard et 
al. 2002; Strauss et al. 2008).  
Deletion of F0 subunit in yeast abolishes dimerization and leads to abnormal 
cristae structure (Minauro-Sanmiguel et al. 2005). Similarly, deletion of MCL-1 results in 
diminished ATP synthase dimer and oligomer assembly and disrupted mitochondrial 
cristae (Perciavalle et al. 2012). Therefore, MCL-1 may act to stabilize the ATP synthase 
complex, but the mechanism is unknown. 
Mitochondria are dynamic organelles constantly undergoing fusion and fission.  
At steady state, the frequency of fusion and fission events is balanced to maintain the 
overall normal mitochondrial morphology. Disruption of this balance leads to dramatic 
change in mitochondrial morphology (Detmer and Chan 2007). Fused mitochondria 
exhibit elongated, spaghetti-like shape and are extremely interconnected, whereas fissed 
mitochondria show smaller and fragmented morphology (Detmer and Chan 2007). 
Mitochondrial fusion enables the exchange of contents between mitochondria, which is 
pivotal for maintaining mitochondrial homeostasis. Mitochondria with impaired fusion 
machinery have reduced respiratory capacity, increased ROS production, and induction 
of mtDNA deletion or mutations (Chen et al. 2005a; Chen et al. 2007; Chen et al. 2010). 
The mtDNA genome encodes the essential subunits of ETC complexes I, III, IV and V, 
and therefore is critical for OXPHOS. In the absence of matrix-localized MCL-1, 
mitochondria exhibit fragmented morphology and less IMM fusion (Perciavalle et al. 
2012). Consequently, fusion deficiency could be a possible explanation for decreased 
levels of mtDNA and subsequent bioenergetic abnormalities observed in Mcl-1-deleted 
mitochondria.  
Cardiomyocyte Death and Heart Disease 
From early embryogenesis through adulthood, the heart is pivotal for all the 
physiological processes. Thus, it is not surprising that primary and secondary heart 
diseases can have catastrophic consequences and are the most costly and common causes 
of adult death worldwide (NHLBI 2012). Insults including ischemia, hypoxia, toxins and 
drugs can cause heart diseases, which are associated with loss or dysfunction of 
cardiomyocytes, diminished pump function, abnormal conduction, eventual heart failure 
and death.  
Adult cardiomyocytes are limited in their ability to re-enter the cell cycle, and 
thus have limited capacity for self-renewal. In mice, when the ventricle apex of the heart 
is amputated at postnatal day 1 (P1), the heart can undergo full regeneration without scar 
formation. However, this regenerative ability of neonatal heart is lost after P7 and 
extensive cardiac fibrosis is observed (Porrello et al. 2011). Although it is reported that in 
young adult mice under normal homeostatic conditions, cardiomyocyte renewal from pre-
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existing myocytes can occurs at a low rate (0.76 % per year and decline at age), and 
increases upon injury, this limited capacity of renewal is still insufficient for regeneration 
in response to various insults (Senyo et al. 2013). Thus, the heart is particularly sensitive 
to cardiomyocyte death and exploring how cell death is regulated is critical to developing 
potential strategies for preventing cardiac damage and preserving cardiac function. 
  
Cardiomyocyte death is a hallmark in the progress of various heart diseases, in 
which cells die primarily through apoptosis and/or necrosis, and autophagy, which has 
been associated with cell death as well (Whelan et al. 2010).  
Apoptosis and Heart Disease 
Atherosclerotic vascular disease is the major cause of myocardial infarction and 
heart failure and the disruption of the atherosclerotic plaque is the leading factor of acute 
coronary syndrome. It is reported that apoptotic macrophages and smooth muscle cells in 
the plaque can lead to the accumulation of lipid-rich core to facilitate the disruption of 
plaque and thrombosis (Kockx et al. 1998; Clarke et al. 2008). Reperfusion is the 
treatment for myocardial infarction, but the reintroduction of oxygen to the infarct area 
can lead to reperfusion injury. The presence of apoptotic cardiomyocytes has been 
identified as a significant component of cell loss during reperfusion and contributes to the 
development of cardiac remodeling and heart failure after myocardial infarction (Gottlieb 
et al. 1994; Saraste et al. 1997; Levine and Klionsky 2004).  
Moreover, increased levels of apoptotic cardiomyocytes have been observed in 
the hearts of diabetic patients and are implicated in the development of diabetic 
cardiomyopathy (Cai et al. 2002; Li et al. 2007). Hyperglycemia appears to play a critical 
role in the pathogenesis of diabetic cardiomyopathy by the induction of cardiomyocyte 
apoptosis via increased level of ROS and nitrogen species (Cai and Kang 2001). Studies 
have shown that antioxidants and apoptotic inhibitors can significantly prevent the 
development of cardiomyopathy suggesting that oxidative stress-mediated apoptosis 
plays an important role in this process (Ye et al. 2003; Song et al. 2005).  
The gp130 is a common subunit of cytokine receptor for the interleukin-6 family 
and has been shown to promote cell survival under apoptotic stress in vitro. The cardiac-
specific gp130 knockout mice reveal grossly normal phenotype, but develop significant 
cardiomyocyte apoptosis (? 34%) and mostly die within weeks after being exposed to an 
acute pressure load by surgical constriction of the transverse aorta (Hirota et al. 1999). 
On the other hand, the overexpression of heterotrimeric G proteins, such as Gq? or Gs? in 
the cardiomyocytes may promote apoptosis under stress. Pregnant transgenic mice with 
Gq? overexpressed in the heart develop lethal dilated cardiomyopathy within one week 
after delivery and TUNEL staining reveals a markedly increased level of cardiomyocyte 
apoptosis (? 26%) (Adams et al. 1998). Overexpression of Gs? in the heart also results in 
increased apoptosis and leads to cardiomyopathy and blocking the ?-adrenergic receptor 
could prevent cardiac damage, decrease cardiac apoptosis and preserve cardiac function 
(Asai et al. 1999; Geng et al. 1999). 
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Chronic heart failure is the end-stage of various heart diseases and apoptosis has 
also been revealed to play an important role in the progression of this disease. It is 
reported that patients with chronic heart failure have higher level of cardiomyocyte 
apoptosis than normal subjects (0.08-0.25 vs. 0.001-0.002%) (Saraste et al. 1997; Guerra 
et al. 1999; Levine and Klionsky 2004). Moreover, genetic and pharmacological studies 
on animal models suggest a role for cardiomyocyte apoptosis in the progression of 
chronic heart failure. Kitsis et al. generated transgenic mice overexpressing cardiac-
specific ligand-activatable Caspase-8, which is a fusion protein consisting of a FK506 
binding domain and the Caspase-8 catalytic domain. Transgenic mice expressing this 
fusion protein reveal no obvious observable phenotype after birth, but administration of 
the dimerizer FK1012, which activates Caspase-8 and in turn Caspase-3, leads to 
overwhelming cardiomyocyte apoptosis and not surprisingly, rapid death of the animal. 
However, even in the absence of FK1012, transgenic mice with high expression of the 
fusion protein still exhibit a low level of spontaneous apoptosis (lower than 0.1% whereas 
wild type mice is less than 0.002%) in the heart, leading to a severe dilated 
cardiomyopathy over 8 weeks and death within 2-6 months after birth. Prevention of 
cardiomyocyte apoptosis with a caspase inhibitor can ameliorate the cardiac dilation and 
improve cardiac function (Wencker 2003). This suggests that even a very low level of 
apoptosis can contribute to the pathogenesis of dilated cardiomyopathy and heart failure. 
The major signaling pathways involved in the cardiomyocyte apoptosis include 
the intrinsic apoptosis pathway (mitochondrial death pathway), extrinsic apoptosis 
pathway (death receptor pathway), and endoplasmic reticulum (ER)-stress death pathway. 
The Intrinsic Apoptosis Pathway and Heart Disease. Just like other cell types, 
mitochondria play a central role in the initiation and regulation of the intrinsic apoptosis 
pathway in cardiomyocytes. In response to various stresses including nutrient deprivation, 
oxidative stress and DNA damage, mitochondria release several apoptogenic proteins 
such as cytochrome c, apoptosis inducing factor (AIF), endonuclease G (Endo G), second 
mitochondria-derived activator of caspases (Smac/Diablo), and HtrA2/Omi to induce 
apoptosis. This pathway appears to play a significant role particularly in 
ischemia/reperfusion injury and heart failure (Chen et al. 2002; Scarabelli et al. 2002). 
Abundant evidence demonstrates that BCL-2 family members also tightly 
regulate the intrinsic apoptosis pathway in the myocardium. And the balance between 
pro- and anti-apoptotic BCL-2 proteins can determine the outcome of pathological 
processes in the heart (Latif et al. 2000; Baldi et al. 2002; Di Napoli et al. 2003).  
Anti-apoptotic BCL-2 Family Members. Anti-apoptotic BCL-2 family members 
have been shown to protect cardiomyocytes from various stresses and considered to have 
therapeutic potential in several cardiac disease models. For example, BCL-2 can prevent 
p53-mediated cardiomyocyte apoptosis (Kirshenbaum and de Moissac 1997).  Transgenic 
mice with BCL-2 overexpressed in the heart have fewer apoptotic cells, reduced infarct 
size, improved cardiac function and prolonged survival time after ischemia/reperfusion 
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injury (Brocheriou et al. 2000; Chen et al. 2001; Imahashi et al. 2004). Desmin knockout 
mice develop cardiomyopathy characterized by extensive fiber loss, mitochondrial 
damage and later heart failure (Milner et al. 1996; Milner et al. 1999). And 
overexpression BCL-2 in the heart can attenuate the cardiomyopathy phenotype by 
blocking apoptotic cell death and preventing mitochondrial defects (Milner et al. 2000; 
Weisleder et al. 2004; Maloyan et al. 2010). In addition, overexpression of BCL-XL in 
H9c2 cardiac cells inhibits doxorubincin and hypoxia-induced apoptosis (Reeve et al. 
2007). Transgenic mice with increased accumulation of mtDNA mutation reveal a strong 
pro-survival response by upregulating BCL-2 and BCL-XL (Zhang et al. 2005).  
Moreover, other protective functions of BCL-2 have also been identified. One 
mechanism for ischemic damage is the inhibition of mitochondrial ATP production due 
to lack of oxygen, which induces F1F0-ATPase running inversely to consume glycolytic 
ATP, leads to energy depravation (Rouslin et al. 1986; Vuorinen et al. 1995). 
Furthermore, overexpression of BCL-2 in the heart decreases the rate of ATP decline and 
reduces acidification, suggesting that BCL-2 may protect myocardium during ischemia 
by inhibiting consumption of glycolytic ATP generated by inversed F1F0-ATPase 
(Imahashi et al. 2004). Additionally, during ischemia, the sodium calcium exchanger 
(NCX) extrudes Na+ and the cells become overloaded with Ca2+ (Karmazyn and Moffat 
1993). BCL-2 has been shown to reduce the NCX activity and increase resistance to 
mitochondrial permeability transition by increasing the Ca2+ threshold for the opening of 
mitochondrial permeability transition pore (mPTP) in the heart (Zhu et al. 2001). These 
studies indicate that anti-apoptotic BCL-2 proteins can protect cardiomyocytes from cell 
death through multiple mechanisms and have promising therapeutic potentials to prevent 
and treat heart diseases. 
Pro-apoptotic BCL-2 Family Members. The pro-apoptotic BCL-2 proteins have 
been implicated in the pathogenesis of various heart diseases. The pro-apoptotic BH3-
only proteins function as stress sensors and integrate cell death stimuli. Several BH3-only 
proteins including BID, BAD, PUMA, BNIP3 and NIX/BNIP3L, have been implicated in 
cardiomyocyte death. BID is cleaved during myocardial ischemia/reperfusion, resulting 
in the release of cytochrome c to induce apoptosis. BAD is significantly induced during 
ischemia/reperfusion accompanied by a reduction in BCL-2 and BCL-XL (Murriel et al. 
2004). Puma is induced in cardiomyocytes upon hypoxia-reoxygenation, and deletion of 
Puma decreases infarct size and improves cardiac function after ischemia/reperfusion 
(Toth et al. 2006). BNIP3 and NIX/BNIP3L are two BH3-only proteins that have been 
extensively studied in the heart. These two proteins are upregulated in response to various 
stresses by different pathways: BNIP3 by hypoxia via hypoxia induced factor-1? (HIF-1?) 
and E2F-1 (Bruick 2000; Kubasiak et al. 2002; Regula et al. 2002; Galvez et al. 2006; 
Yurkova et al. 2008), and NIX by Gq ?-mediated stimuli, such as phenylephrine (Galvez 
et al. 2006). BNIP3 is activated by oxidative stress during myocardial reperfusion and 
then activates downstream BAX and BAK to induce apoptosis (Kubli et al. 2008). In 
addition, NIX/BNIP3L has also been associated with cardiac hypertrophy and 
development of cardiomyopathy (Diwan et al. 2008)
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Activation of BH3-only proteins in response to stress induces the activation of 
BAX and BAK. Activated BAX and BAK undergo oligomerization and induce the 
permeabilization of the outer mitochondrial membrane (OMM) allowing the release of 
apoptogenic proteins from the intermembrane space. Therefore BAX and BAK are 
essential for the mitochondrial death pathway. BAX is activated in cardiomyocyte in 
response to oxidative stress (Gustafsson et al. 2004). During ischemia, BAX is 
translocated to mitochondria and this is shown to be dependent on AMPK and p38 
MAPK in neonatal cardiomyocytes (Capano and Crompton 2006). Moreover, BAX 
deficient mice revealed less mitochondrial damage and reduced infarct size after 
ischemia/reperfusion injury (Hochhauser et al. 2003), indicating that BAX is important in 
this process. 
The Extrinsic Apoptosis Pathway and Heart Disease. Several studies have 
shown that the extrinsic apoptosis pathway contributes to the pathogenesis of heart 
diseases. Both death receptors Fas and tumor necrosis factor receptor (TNFR1) are 
presented in cardiomyocytes. It is reported that the ligand of TNFR1, TNF-?, is abundant 
in cardiomyocytes (Giroir et al. 1992; Kapadia et al. 1995), and its expression in failing 
human myocardium is higher than non-failing heart (Doyama et al. 1996; Torre-Amione 
et al. 1996). Patients with end-stage congestive heart failure have elevated circulating 
TNF-?, and its level is related to the severity of the disease (Levine et al. 1990; Dutka et 
al. 1993; Ferrari et al. 1995). In addition, the level of TNF-? in both the heart and 
circulation is increased during ischemia/reperfusion (Jeremias et al. 2000; Gilles et al. 
2003). Transgenic mice with TNF-? overexpressed in the heart developed dilated 
cardiomyopathy and heart failure (Kubota et al. 1997; Bryant et al. 1998), suggesting that 
the TNF-?-mediated death receptor pathway is detrimental to the heart. 
Activation of the Fas induced death receptor pathway has been observed in 
cardiomyocytes, and stress such as hypoxia can induce the expression of both Fas and 
FasL in the cultured cardiomyocytes (Tanaka et al. 1994). There is evidence indicating 
that Fas-mediated apoptosis contributes to myocardial ischemia/reperfusion injury and 
post-infarction remodeling. Studies have shown that mice lacking functional Fas (lpr
mice) are resistant to ischemia/reperfusion injury and have reduced infarct size and 
apoptosis compared to control mice (Jeremias et al. 2000; Lee et al. 2003). During 
myocardial infarction, granulation tissue cells are cleared by apoptosis to complete scar 
formation. Blocking apoptosis could improve post-infarction remodeling and heart failure. 
Both lpr mice and Fas ligand deficient mice (gld mice) revealed significantly fewer 
apoptotic granulation tissue cells compared to control mice, and ventricular remodeling 
and heart failure is attenuated. Mice transfected with adenovirus encoded a competitive 
FasL inhibitor (sFas) on the third day of infarction have alleviated heart failure symptoms 
and prolonged survival (Li et al. 2004). Therefore, Fas-mediated apoptosis plays a role in 
the progression of heart diseases.  
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The ER-stress Death Pathway and Heart Disease. The endoplasmic reticulum 
(ER) is essential for multiple cellular processes, including intracellular calcium 
homeostasis, protein secretion and lipid biosynthesis, which are required for cell survival 
and normal functions. Many insults, including oxidative stress, glucose deprivation and 
aberrant Ca2+ regulation cause the accumulation of unfolded proteins in the ER, 
triggering the unfolded protein response (UPR) to restore ER homeostasis (Szegezdi et al. 
2006b). The UPR activates transcriptional programs to enhance the protein folding 
capacity of the ER, promote the degradation of misfolded proteins and inhibit protein 
synthesis to reduce the influx of new proteins into the ER. Prolonged and excessive ER 
stress causes failure of the UPR and induces cell death typically in the form of apoptosis 
(Xu et al. 2005).  
Many mechanisms have been hypothesized to explain the ER stress-mediated 
apoptosis. It is reported that Caspase-12 is activated upon ER stress, and activated 
Caspase-12 activates Caspase-3 to induce apoptosis (Szegezdi et al. 2006b). ER stress 
also induces the expression of transcriptional factor C/EBP homologous protein 
(CHOP/GADD 153) and p53, increasing the expression of pro-apoptotic proteins such as 
PUMA and NOXA (Li et al. 2006). 
Several studies have demonstrated the contribution of ER stress to heart diseases. 
For instance, pharmacological ER stress inducer induces apoptosis in cultured 
cardiomyocytes, and pressure overload inducing extensive ER stress leads to cardiac 
hypertrophy and heart failure in mice through the CHOP-dependent pathway (Okada et al. 
2004). ER stress is also enhanced during myocardial ischemia/reperfusion injury through 
upregulation of CHOP and activation of Caspase-12, and participates in the development 
of ischemic heart disease (Azfer et al. 2006; Szegezdi et al. 2006a; Thuerauf et al. 2006). 
Evidence also indicates that ER stress mediated apoptosis plays a role in the pathogenesis 
of diabetic cardiomyopathy (Li et al. 2007). Moreover, transgenic mice with mutated 
KDEL receptor (a receptor for ER chaperones) develop dilated cardiomyopathy (Hamada 
et al. 2004). 
Necrosis and Heart Disease 
Cardiomyocyte necrosis has been well described in heart ischemia/reperfusion 
injury and heart failure. Generally, initiators of necrosis include calcium overload, 
hypoxia and ROS (Nakayama et al. 2007). Mitochondrial permeability transition pore 
(mPTP) is considered to be the executor in this event. The mPTP is generally 
hypothesized to consist of the voltage-dependent anion channel (VDAC) on the OMM, 
the adenine nucleotide translocator (ANT) in the IMM, and Cyclophilin-D in the matrix, 
which is still under debate, and only Cyclophilin-D has been shown to be an essential 
component of the mPTP by genetic ablation (Kroemer et al. 2007).  
Cardiomyocytes lacking Cyclophilin-D are resistant to calcium overload and ROS 
damage induced cell death, but still sensitive to apoptotic stimuli. Cyclophilin-D
knockout mice exhibit reduced infarct size after ischemia/reperfusion injury, and 
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overexpression of Cyclophilin-D was able to restore the death response (Baines et al. 
2005; Nakagawa et al. 2005). These studies indicate the importance of Cyclophilin-D 
mediated necrosis in the process of ischemia/reperfusion. In addition, calcium overload in 
transgenic mice results in cardiomyocytes necrosis and heart failure, and the phenotype 
can be rescued by deletion of Cyclophilin-D, suggesting that necrosis mediates heart 
failure (Nakayama et al. 2007). Furthermore, Cyclophilin-D has been shown to be 
involved in the pathogenesis of muscular dystrophy. Genetic ablation and 
pharmacological inhibition of Cyclophilin-D could markedly alleviate the muscular 
phenotype by reducing myofiber necrosis (Millay et al. 2008; Tiepolo et al. 2009). 
More recently, the pro-apoptotic protein BAX is reported to play a role in necrosis. 
Co-deletion of Bax and Bak significantly reduce the infarct size after myocardial 
infraction, however, further deletion of Cyclophilin-D over the Bax and Bak-deficient 
background fails to show additional reduction in infarct size. Bax and Bak-deleted 
mitochondria and cells are resistant to mPTP opening and necrosis. Reconstitution with 
wild-type BAX or an oligomerization-deficient mutant that cannot support apoptosis 
restores the opening of mPTP and necrosis. Furthermore, induction of mitochondrial 
fusion potentiates mPTP opening in the absence of BAX and BAK, indicating that 
deletion of Bax and Bak may also down-regulate necrotic cell death by increasing the 
threshold for the opening of the mPTP (Whelan et al. 2012). Thus, BAX and BAK 
contribute to the pathogenesis of myocardial infarction not only through apoptosis, but 
also through necrosis. 
Autophagy-associated Cell Death and Heart Disease 
In contrast to apoptosis and necrosis, autophagy is primarily a survival 
mechanism. It is a conserved cellular process for degradation and recycling of 
cytoplasmic components, such as long-lived proteins and large organelles. Autophagy 
provides amino acids and fatty acids to cells under nutrient deprivation. However, the 
role of autophagy in cell death is still under debate and seems to be circumstantial and not 
yet defined at the mechanistic level. In the heart, the role of autophagy has been reported 
to be protective as well as deleterious to cardiac function (Nishida et al. 2008). 
Induction of autophagy is observed during myocardial infarction and 
ischemia/reperfusion injury and plays distinct roles during ischemia and reperfusion. 
Energy deprivation in infarction and ischemia activates 5’-adenosine monophosphate-
activated protein kinase (AMPK) to induce autophagy. Transgenic mice with 
overexpression of a dominant-negative AMPK reveal autophagy inhibition and enlarged 
infarct size, suggesting that autophagy promotes survival under this condition (Takagi et 
al. 2007). In contrast, during reperfusion, the enhancement of autophagy is mediated by 
Beclin-1 induction rather than AMPK activation, which is detrimental to the heart, as 
significantly less autophagy and attenuated cardiac injury is observed in Beclin-1+/- mice 
(Matsui et al. 2007). 
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Failing human hearts have increased amount of autophagosomes, indicating the 
induction of autophagy (Hein et al. 2003; Kostin et al. 2003). The consequences of 
autophagy enhancement in heart failure have been addressed by several studies. Cardiac-
specific deletion of Atg-5 during adulthood leads to cardiac hypertrophy, left ventricular 
dilation, loss of cardiac contractility, abnormal sarcomere and mitochondrial structure, 
accumulation of ubiquitinylated protein and cardiomyocyte apoptosis. Deletion of Atg-5
at embryonic day (E) 7.5-8 exhibits no cardiac phenotype due to presumable 
compensation. However, hemodynamic overload or ?-adrenergic stimulation leads to 
cardiac dysfunction, left ventricle dilation, and fatal heart failure thereafter (Nakai et al. 
2007). This study indicates that autophagy is protective for heart under basal conditions 
and induction of autophagy is a compensatory mechanism for heart failure. In another 
study, heterozygous disruption of Beclin-1, a protein required for early autophagosome 
formation, decreases autophagy, attenuates severe pressure load-induced cardiac 
remodeling and heart failure. Conversely, overexpression of Beclin-1 enhances 
autophagy and accentuates pathological remodeling (Zhu et al. 2007). This study 
concludes that autophagy plays a role in the pathogenesis of pressure overload-induced 
heart failure, which is controversial to the first study. Moreover, Beclin-1+/- has been used 
to access the role of autophagy in Desmin-related cardiomyopathy. Heterozygous 
disruption of Beclin-1 leads to decreased autophagy, accumulation of ubiquitinylated 
proteins, fibrosis, heart failure and increased mortality (Tannous et al. 2008). This study 
concludes that autophagy plays a protective role in Desmin-related cardiomyopathy. Thus, 
further studies need be done to clarify the different roles of autophagy in heart failure. 
Mitochondria and Heart Disease 
Mitochondria are cytoplasmic double-membrane organelles, which have long 
been known to play a pivotal role in the life of the cell. They carry out the energy-
yielding OXPHOS that provides the most of ATP necessary for all cellular functions. 
Interruption of mitochondria function, for example by cyanide poisoning, rapidly causes 
death in vivo (Newmeyer and Ferguson-Miller 2003). Mitochondria OXPHOS generates 
ATP and water via oxidation of hydrogen from carbohydrates and fats. Hydrogen from 
carbohydrates is recovered through the tricarboxylic acid (TCA) cycle, while hydrogen 
from fats is recovered through fatty acid ?-oxidation. Electrons from hydrogen are either 
stripped to nicotinamide adenine dinucleotide (NAD+) to produce NADH+H+ and then 
transferred to electron transport chain (ETC) complex I (NADH dehydrogenase), or to 
flavin adenine dinucleotide (FAD) to generate FADH2 and then transferred to complex II 
(succinate dehydrogenase, SDH). The electrons are sequentially passed to ubiquinone 
(coenzyme Q, CoQ) to give ubisemiquinone and ubiquinol. Ubiquinol transfers the 
electrons to complex III (ubiquinol:cytochrome-c oxidoreductase), cytochrome-c, 
complex IV (cytochrome-c oxidase, COX) and finally to oxygen to give H2O. The energy 
released by the ETC is used to pump protons out across the IMM to generate the proton 
electrochemical gradient. The potential energy stored in the proton gradient is used to 
condense ADP + Pi to ATP via complex V (ATP synthase), driven by the flow of protons 
from the intermembrane space back into the mitochondrial matrix through the complex V 
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proton channel. Matrix ATP is then exchanged for cytosolic ADP by the IMM ANTs 
(Goldstein et al. 1999; Wallace 2002; Wallace and Fan 2009) (Figure 1-5).  
Mitochondrial OXPHOS also generates the ROS (O2.-, H2O2, and OH.) as 
byproducts.  When ETC is inhibited, the electrons from complex I can be transferred to 
the O2 on the matrix side of the IMM or from complex III to O2 on the cytosolic side of 
the IMM to generate superoxide anion (O2.-). O2.- then is further converted to hydrogen 
peroxide (H2O2) by either matrix-specific manganese superoxide dismutase (MnSOD) 
encoded by nuclear DNA (nDNA) Sod 2 gene or IMS and cytosolic  Cu/ZnSOD encoded 
by Sod 1 gene. H2O2 is converted to H2O by glutathione peroxidase (GPx). H2O2 can also 
be converted to the highly reactive hydroxyl radical (OH.) in the presence of reduced 
transition metals, which is the most potent oxidizing agent among the ROS (Figure 1-5). 
ROS are toxic byproducts for cells. Acute ROS exposure can inactivate the iron-sulfur 
(Fe-S) center of ETC complex I, II, III, and TCA aconitase, blocking the energy 
production of mitochondria. Chronic ROS exposure can lead to oxidative damage to 
mitochondrial and cellular DNA, proteins and lipids, and finally affect a variety of 
cellular processes (Wallace 1999; Wallace 2002; Wallace and Fan 2009). 
In addition to being the “powerhouse” and endogenous ROS resource of the cell, 
mitochondria are also involved in many other processes, such as cell death (discussed 
intensively in previous section), development, cell cycle, and cellular signaling (McBride 
et al. 2006). Therefore, mitochondria have been implicated in many human diseases, 
which have been recapitulated in several mouse models. It is now clear that 
mitochondrial dysfunction can cause an assemblage of clinical problems and commonly 
present in tissues with high-energy requirements, such as heart, muscle, liver, kidney, 
nervous system and endocrine system (Wallace 1999; Wallace 2002).  
Mitochondria in the Heart 
As the hardest working organ in body, the heart produces and utilizes 
approximately 30 kg of ATP every day to keep basal metabolism and normal heart 
contraction for sustaining systemic and pulmonary blood pressure (Ferrari 2003). ATP is 
the primary source of energy for the physiological functions of the heart, including 
contraction, relaxation, electrical excitation and recovery of the resting electrochemical 
gradients across membranes. Under physiological conditions, 90% of heart’s ATP is 
produced in cardiomyocyte mitochondria by oxidative phosphorylation (Das 1991). 
Substrate oxidation in heart changes during organ development. The fetal and newborn 
heart uses glucose and lactate as the main sources of energy, whereas the postnatal heart 
preferentially oxidizes fatty acids and produces energy sequentially through ?-oxidation, 
Kreb’s cycle and the respiratory chain (Carvajal and Moreno-Sanchez 2003). 
Ultrastructural studies have revealed that cardiac muscle is packed with mitochondria, 
accounting for ~35% of myocardial mass (Sommer and Waugh 1978), making the 
myocardium one of the most mitochondria-rich tissues.  In normal myocardium, 
mitochondrial are usually tightly aligned between myofibrils, but are also found beneath 
?
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Figure 1-5 Mitochondria and cancer 
Mitochondria lie at the nexus of most biosynthetic pathways, produce much of the 
cellular energy through oxidative phosphorylation (OXPHOS), regulate mitochondrial 
and cellular redox status, generate most of the reactive oxygen species (ROS), regulate 
Ca2+ concentrations and can initiate apoptosis by the activation of the mitochondrial 
permeability transition pore (mtPTP). The mtPTP can be activated by a decreased 
membrane potential, high-energy phosphates (such as ADP), a more-oxidized redox 
status, and/or increased mitochondrial matrix Ca2+ and ROS concentrations. Reducing 
equivalents and acetyl-CoA enter the mitochondrion via pyruvate and fatty acids. 
Pyruvate is transported through the mitochondrial inner membrane by the pyruvate 
transporter (PT)118, binds to pyruvate dehydrogenase (PDH), which may be membrane-
associated, and is oxidatively decarboxylated to produce acetyl-CoA. Inhibition of 
mitochondrial function results in pyruvate accumulation in the cytosol, where it can be 
reduced to lactate. Fatty acids are imported into the mitochondrion bound to carnitine. In 
the cytosol, fatty acids bound to CoA are transferred to carnitine, transported through the 
outer and inner mitochondrial membranes, and then transferred back to CoA for ?-
oxidation. The transfer of fatty acyl groups between CoA and carnitine is mediated by the 
carnitine palmitoyltransferases (not shown). As a by-product of OXPHOS — the 
substrates and products of which are transported through the outer membrane by the 
voltage-dependent anion channels (VDACs) — mitochondria generate ROS by the 
donation of excess electrons from complexes I and III directly to O2 to generate 
superoxide anions (O2•−). Matrix O2•−, primarily from complex I, is dismutated to 
H2O2 by the mitochondrial matrix Mn superoxide dismutase (MnSOD; also known as 
SOD2), while intermembrane-space O2•−, which is primarily from complex III, is 
dismutated by Cu/Zn superoxide dismutase (Cu/ZnSOD; also known as SOD1). H2O2 
can be reduced to water by glutathione peroxidase using reduced glutathione as an 
electron donor. Oxidized glutathione is reduced by glutathione reductase using NADPH 
as a reductant. In the presence of reduced transition metals, H2O2 can be reduced to 
hydroxyl radicals (•OH), which are the most reactive ROS. The mtPTP is a protein 
complex that is thought to include the translocator protein (TSPO; also known as PBR), 
an unknown inner-membrane channel, adenine nucleotide translocators (ANTs) and the 
cyclosporine-A-sensitive cyclophilin D (CYPD; also known as PPID), which are 
regulatory, in association with the BCL-2 pro- and anti-apoptotic family members. When 
activated, the mtPTP forms a channel between the inner and outer membranes, which 
short-circuits ?P. This is associated with the aggregation of BAX and BAD in the 
mitochondrial outer membrane to form a megachannel. The megachannel releases pro-
apoptotic proteins from the intermembrane space into the cytosol to initiate the 
degradation of the cellular proteins and DNA. AIF, apoptosis-inducing factor; CoA-SH, 
coenzyme A with a free sulphydryl group; CoQ, coenzyme Q10; ENDOG, mitochondrial 
endonuclease G; GPX, glutathione peroxidase; LDH, lactate dehydrogenase; OAA, 
oxaloacetate; SMAC, second mitochondria-derived activator of caspase; TCA, 
tricarboxylic acid. Reprinted with permission from Macmillan Publishers Ltd: Wallace 
DC. 2012. Mitochondria and cancer. Nature Reviews Cancer 12: 685-698. 
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the sarcolemma or segregating at the ends of the nucleus. This strategic mitochondrial 
distribution allows for efficient ATP supply to high energy demanding, contracting 
cardiomyocytes (Milner et al. 2000).  
As cardiac function is highly dependent upon ATP produced by mitochondrial 
oxidative phosphorylation, cardiac mitochondrial abnormalities leading to decreased ATP 
generation can cause cardiomyopathy, cardiac dysfunction, heart failure and even death 
(Antozzi and Zeviani 1997).  
Mitochondrial Cardiomyopathies 
The mitochondria are composed of more than 1000 polypeptides, mostly encoded 
by nDNA. However, thirteen polypeptides are encoded by the mtDNA, all of which are 
essential components of OXPHOS ETC complexes. They are seven of the 43 subunits of 
complex I (ND1, 2, 3, 4, 4L, 5, 6), one of the 11 subunits of complex III (cytb), three of 
the 13 subunits of complex IV (COXI, II, III), and two of the 16 subunits of complex V 
(ATP 6 and 8). The mtDNA also codes for the 12S and 16S rRNAs and 22 tRNAs, which 
are necessary for the synthesis of mitochondrial proteins (Wallace 2002; Wallace and Fan 
2009). Mutation in mtDNA or nDNA, leading to mitochondrial protein deficiencies, can 
cause diseases with cardiomyopathy. 
Cardiomyopathies are heart diseases that cause heart failure, arrhythmia and 
sudden death. Sequence change in both mitochondrial genome and nuclear genome can 
cause cardiomyopathies. Moreover, mutations of nuclear genes can not only cause the 
change of mtDNA structure and content, but also can directly affect the integrity and 
maintenance of mitochondrial ETC complexes, causing mitochondrial dysfunction and 
inducing disease (Schapira 2012). Of the 1000 genes encoding mitochondrial proteins, 
mutations in 228 protein-encoding nuclear DNA genes and 13 mtDNA genes have been 
linked to human cardiomyopathies (Koopman et al. 2012).  
Mutations in nDNA can also lead to mitochondrial-associated cardiomyopathies 
since most mitochondrial proteins are encoded by the nuclear genome. For example, 
mutations of the nuclear gene encoding NDUFV2 and NDUFS2 subunits for complex I 
have been strongly linked with early onset hypertrophic cardiomyopathy (Benit et al. 
2003). Deletion of Ant1 in the heart also leads to the development of cardiomyopathy, 
since this abolishes exchange of ADP and ATP across mitochondrial membranes and 
dramatically increases ROS production. In addition, deletion of the Sod2 gene encoding 
ROS detoxification enzyme MnSOD leading to cardiomyopathy, indicates the importance 
of ROS in the pathogenesis of cardiomyopathy as ROS can cause mtDNA damage and 
inactivate iron-sulfur center on the ETC (Esposito et al. 1999). Recently, dilated 
cardiomyopathy induced by conditional deletion of optic atrophy-1 (Opa-1) and 
mitofusin (Mfn) 1/2 suggests that proteins regulating mitochondrial dynamics play an 
essential role in cardiac function (Chen et al. 2011; Chen et al. 2012; Dorn 2013). 
Furthermore, mutations in genes encoding contractile and structure proteins, such as ?-
myosin heavy chain, cardiac troponin T or I, and myosin binding protein C, have been 
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reported to cause hypertrophy cardiomyopathy (Goldstein et al. 1999). Deficiency in the 
lipid content of mitochondria has also been implicated to cardiomyopathy. Barth 
syndrome, an X-linked cardiomyopathy, is caused by a defect in the cardiolipin 
transacylase enzyme, tafazzin. Optimal cardiolipin content is essential for proper function 
and organization of various mitochondrial enzymes. Mutations in tafazzin gene have been 
reported to result in reduced mitochondrial cardiolipin content. Patients show 
mitochondrial ultrastructural abnormalities, reduced OXPHOS, left ventricular 
dysfunction and dilation (Hauff and Hatch 2006; Schlame and Ren 2006; Claypool et al. 
2008). 
Mitochondria and Heart Failure 
The involvement of mitochondria in the progression of heart failure was indicated 
as early as 1962 in a guinea pig model, in which reduced mitochondrial OXPHOS was 
observed (Schwartz and Lee 1962). It is well established that mitochondria-mediated cell 
death plays important roles in the pathogenesis of heart failure (covered previously). 
However, it is becoming more evident that mitochondria also contribute to the 
development of heart failure via mitochondrial ROS and calcium. 
Since the heart is the most mitochondria enriched organ, mitochondrial-generated 
ROS is the major player of oxidative stress to the heart (Sommer and Waugh 1978). The 
toxic ROS have deleterious effects on mitochondrial and nuclear DNA, proteins, cell 
structure, and act as signaling molecules for the progression of heart failure. The mtDNA 
are more susceptible to ROS damage than nDNA since they have poor DNA repair 
mechanism and no protective histones. Moreover, O2.- generated by OXOPHOS is not 
well membrane permeable and mostly is trapped within the mitochondria to cause the 
damage (Murphy 2009; Tsutsui et al. 2009). It is reported that the mutation rate of 
mtDNA is ten times more than the nDNA (Chen et al. 2006). There is evidence that ROS 
production is induced in patients with heart failure as well in animal models (Mallat et al. 
1998; Ide et al. 2000). Therefore, strategies that upregulate the antioxidant defense 
pathways are candidates for the prevention or treatment of heart failure. Overexpression 
of the antioxidative enzyme Gpx can prevent the development of heart failure after 
myocardial infarction in mice (Shiomi et al. 2004). MitoQ10, an ubiquinol antioxidant, 
has been shown to be beneficial in protecting cardiac dysfunction and heart failure 
following ischemia/reperfusion injury (Adlam et al. 2005), hypertension and hypertrophy 
(Graham et al. 2009), sepsis-induced cardiac dysfunction (Supinski et al. 2009). In 
addition, dietary supplementation with vitamin E to rats can also protect against heart 
failure by increasing the activity of catalase and Gpx (Hill et al. 2005).  
Mitochondrial calcium has been implied to mediate the opening of the mPTP to 
induce cell death to contribute to the pathogenesis of heart diseases, especially during 
ischemia/reperfusion injury. However, mitochondrial calcium also regulates energy 
metabolism to produce ATP. In cardiomyocytes, close apposition with the ER allows 
mitochondria to rapidly take up calcium released from ER. It is reported that an increase 
in mitochondrial calcium concentration results in activation of key mitochondrial 
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metabolic enzymes, including pyruvate, ?-ketoglutarate and isocitrate dehydrogenases to 
increase NADH production and in turn ATP production (McCormack et al. 1990; 
Jouaville et al. 1999; Balaban 2002; Rosca and Hoppel 2010). In animal models with 
heart failure, there is a parallel reduction of ETC complexes activity and mitochondrial 
calcium uptake (Lin et al. 2007). Mitochondrial calcium also plays a role in regulating 
ROS. In animal models with heart failure, increasing mitochondrial calcium can reduce 
the induction of ROS. Conversely, the ROS production is enhanced in the presence of 
Ru360, which blocks mitochondrial calcium uptake. Cardiomyocytes isolated from the 
failing heart also show elevated mitochondrial ROS production and can be prevented by 
inhibiting mitochondrial sodium calcium exchanger (Kohlhaas et al. 2010). Thus, it is 
clear that mitochondrial ROS and calcium contribute to the development of heart failure. 
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CHAPTER 2.   MATERIALS AND EXPERIMENTAL PROCEDURES* 
Mice 
Mcl-1 conditional and Bax conditional Bak-/- mice have been described 
previously (Opferman et al. 2003; Takeuchi et al. 2005).  Ckmm-Cre mice (obtained from 
The Jackson Laboratory, strain name B6.FVB(129S4)-Tg(Ckmm-cre)5Khn/J) were 
described previously (Li et al. 2000). Myh-CreER mice (obtained from The Jackson 
Laboratory, strain name B6.FVB(129)-Tg(Myh6-cre/ Esr1*)1Jmk/J) were described 
previously (Sohal et al. 2001). To induce deletion, mice received five doses of tamoxifen 
(1 mg per dose; Sigma) emulsified in sunflower oil vehicle (Sigma) by gavage. All mice 
were on a mixed 129/C57BL6 background and littermate controls were used. The mice 
were bred in accordance with the institutional animal care and use committee at St. Jude 
Children’s Research Hospital. All mice used in the present studies were maintained in 
specific pathogen-free conditions and littermate controls were used as negative controls. 
Echocardiograph 
Mice were shaved and anesthetized with 0.5%–1.5% isoflurane in a 95% O2, 5% 
CO2 chamber prior to echocardiograph (ECHO). ECHO was performed using VEVO-
2100 high-frequency ultrasound instrumentation (Fujifilm VisualSonics, Inc.) equipped 
with a MS- 550D transducer operating at 40 MHz. All scans were taken with the heart 
rate between 300 and 400 beats per minute (bpm). M-Mode data were obtained in the 
parasternal short axis (PSAX) orientation to determine contractility of the heart. Data 
were post-processed using dedicated VisualSonics software (2100- 1.4.0), and direct 
measurements were determined for IVS, LVPW, and LV dimensions at diastole and 
systole. From these data, EF and FS were determined to assess contractility. 
Histology 
Heart and skeletal muscle tissue was fixed in 10% neutral buffered formalin, 
embedded in paraffin, and cut into 4-um thick sections using HM500M cryostat 
(Microm). The paraffin sections were stained with hematoxlyn and eosin (H&E) and 
Masson’s trichrome stain. Paraffin sections were deparaffinized, and 
immunohistochemistry for detection of Capase-3 and Caspase-7 was performed using the 
following antibodies: anti- cleaved Caspase-3 and Caspase-7 (BioCare Medical).  
-------------------- 
* Reprinted with permission from Cold Spring Harbor Laboratory Press: Wang X, 
Bathina M, Lynch J, Koss B, Calabrese C, Frase S, Schuetz JD, Rehg JE, Opferman JT. 
2013. Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction. 
Genes & development 27: 1351-1364. 
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Anti-rabbit on rodent polymer (BioCare Medical) with deaminobenzidine detection 
system was used for visualization of the antigen. The number of total and positive nuclei 
was manually counted. Ten fields through the heart were analyzed for each animal under 
20 × magnification. 
Western Blotting and Antibodies 
Immunoblot analysis was performed as previously described (Stewart et al. 2010). 
Briefly, samples were lysed in radioimmunoprecifitation assay (RIPA) buffer (50 mM 
Tris-HCl at pH 7.4, 150 mM NaCl, 1% TritonX-100, 1 mM EDTA, 1% sodium 
deoxycholate, 0.1% SDS) containing protease inhibitors (Roche) on ice. Lysates were 
cleared by centrifugation, and protein concentrations were determined by BCA assay 
(Pierce). The following antibodies were used: anti-MCL-1 (Rockland Immu- 
nochemical), anti-BAX (Millipore), anti-BAK (Millipore), anti- Actin (Millipore), anti-
MnSOD (BD Biosciences), anti-Prohibitin (Thermo Fisher Scientific), anti-BIM 
(Millipore), anti-BNIP3 (Cell Signaling), and anti-BID (Cell Signaling). 
Isolation and Purification of Mouse Heart Mitochondria 
Mice were sacrificed with CO2, and beating hearts were re- moved. Hearts were 
rinsed by ice-cold mito isolation buffer (MIB; 200 mM mannitol, 68 mM sucrose, 10 mM 
HEPES-KOH at pH 7.4, 10 mM KCl, 1 mM EDTA, 1 mM EGTA, 0.1% BSA) to remove 
the blood and then finely minced. Minced tissue was homogenized with a Polytron tissue 
grinder at 12,000 rpm for 2.5 sec and then hand-homogenized in a Potter-Helvehjem 10-
mL homogenizer (Teflon glass) for three to five strokes. Mitochondria were isolated by 
differential centrifugation. Briefly, the homogenized tissue was centrifuged twice at 600g 
for 5 min. The resulting pellet was resuspended in MIB and centrifuged at 5500g for 10 
min. The final pellet was rinsed and gently homogenized in MIB. Concentration of 
mitochondria was determined by Bradford assay. 
Oxygen Consumption 
Mitochondria respiration was measured by a Clark-type oxygen electrode 
(Hansatech Oxygraph) in 500 μl Mito Assay Buffer (MAB) (70 mM Sucrose, 220 mM 
Mannitol, 10 mM Pi, 5 mM Mgcl2, 2 mM Hepes, 1 mM EGTA, 0.2% BSA) at 37°C. 
Complex I respiration was stimulated by the addition of Glutamate (5 mM) and malate 
(2.5 mM). State 3 respiration was stimulated by the addition of ADP (150 ?M). State 4 
respiration is the rate after adding oligomycin (2 ?g/ml). Maximum respiration is 
obtained by the addition of FCCP (0.4 ?M). RCR is the ratio between state 3 and state 4. 
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Enzymatic Assays 
The activity of complex I was assayed as previously described (Frost et al. 2005). 
Complex II activity was assayed by measuring succinate-dependent reduction in DCIP, 
mediated by CoQ1. The reaction was followed by absorbance at 600 nm following 
succinate addition (Miyadera et al. 2003). Complex IV activity was assayed by measuring 
oxidation of cytochrome c at 550 nm and calculated using the extinction coefficient of 
19.6 mM-1cm-1 as previously described (Miro et al. 1998). Pyruvate dehydrogenase 
(PDH) activity was assayed by measuring the pyruvate-dependent reduction of INT, 
mediated by PMS, as previously described (Hinman and Blass 1981). 
DNA Isolation and Quantification 
DNA was extracted from the heart tissue of mice. To quantify the amount of 
mtDNA present per nuclear genome, we used the following primers: 
mtDNA forward primer, 5'-CCTATCACCCTTGCCATCAT-3';?
mtDNA reverse primer, 5'-GAGGCTGTTGCTTGTGTGAC-3'.??
To quantify nuclear DNA, we used a primer set that detects the Pecam geneon 
chromosome 6: 
nDNA forward primer, 5'-ATGGAAAGCCTGCCATCATG-3';?
nDNA reverse primer, 5'-TCCTTGTTGTTCAGCATCAC-3'. 
The relative copy number was quantified by analyzing the difference in threshold 
amplification between mtDNA and nuclear DNA. Real-time PCR was performed with 
SYBR Green (Bio-Rad) detection using a Bio-Rad iCycler using the ddCt method. The 
assay was done in triplicate for each sample.  
To determine the leakiness of the Myh-CreER, PCR were performed with the 
following primers: 
Flox Mcl-1:  5'-CTGAGAGTTGTACCGGACAA-3';  
Flox Mcl-1: 5’-GCAGTACAGGTTCAAGCCGATG-3’.  
Deleted Mcl-1: 5'-CTGAGAGTTGTACCGGACAA-3’;  
Deleted Mcl-1: 5’-ACGCTCTTTAAGTGTTTGGCC-3’.  
Cre: 5’-CTGCATTACCGGTCGATGCAAC-3’;  
Cre: 5’-TGCTAACCAGCGTTTTCGTTCTGCC-3’. 
RNA Isolation and Quantification 
RNA was extracted from heart tissue of mice by TRIzol (Ambion) and reverse 
transcribed by using SuperScript III first-strand synthesis system (Invitrogen). Real-time 
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PCR with SYBR green (Bio-Rad) detection was performed using a BioRad icycler and 
the following primers:  
mPgc1? forward: 5’-CCCTGCCATTGTAAAGAC-3’;  
mPgc1? reverse: 5’-TGCTGCTGTTCCTGTTTT-3’.  
mTfam forward: 5’-CATTTATGTATCTGAAAGCTTCC-3’;  
mTfam reverse: 5’-CTCTTCCCAAGACTTCATTTC-3’.  
mCpt1b forward: 5’-TCCAGTTGGCTTATCGTGGTG-3’;  
mCpt1b reverse: 5’-CTAACGAGGGGTCGATCTTGG-3’.  
mMcad forward: 5’-GAGCAGGTTTCAAGATCGCA-3’;  
mMcad reverse: 5’-ACTTCGTGGCTTCGTCTAGA-3’.  
mCox5b forward: 5’-GCTGCATCTGTGAAGAGGACAAC-3’;  
mCox5b reverse: 5’-CAGCTTGTAATGGGTTCCACAGT-3’.  
mCox4i forward: 5’-ACCAAGCGAATGCTGAACAT-3’;  
mCox4i reverse: 5’-GGCGGAGAAGCCCTGAA-3’. 
mAtp synthase F1 forward: 5’-TCTCCATGCCTCTAACACTCG-3’; 
mAtp synthase F1 reverse: 5’-CCAGGGTCAACAGACGTGTCAG-3’.  
mCyt c forward: 5’-CCAAATCTCCACGGTCTGTTC-3’;  
mCyt c reverse: 5’-ATCAGGGTATCCTCTCCCCAG-3’.  
mCatalase forward: 5’-GCAGATACCTGTGAACTGTC-3’;  
mCatalase reverse: 5’-GTAGAATGTCCGCACCTGAG-3’.  
mSod1 forward: 5’-CCAGTGCAGGACCTCATTTT-3’;  
mSod1 reverse: 5’-TCCCAGCATTTCCAGTCTTT-3’. 
mSod2 forward: 5’-GCACATTAACGCGCAGATCA-3’;  
mSod2 reverse: 5’-AGCCTCCAGCAACTCTCCTT-3’. 
mActin forward: 5’-GAGACCTTCAACACCCC-3’; 
mActin reverse: 5’-GTGGTGGTGAAGCTGTAGCC-3’. 
ddCt method was used to calculate the mRNA level. The assay was done in 
triplicate for each sample. 
Transmission Electron Microscope 
Hearts were perfused and fixed in 2.5% gluteraldehyde in 0.1 M sodium 
cacodylate buffer and post-fixed in 2% osmium tetroxide in 0.1 M sodium cacodylate 
buffer with 0.3% potassium ferrocyanide. Tissue was stained with 4% aqueous uranyl 
acetate, dehydrated, infiltrated and embedded in epoxy resin.  Ultra-thin sections (80 nm) 
were cut and imaged using a JEOL 1200 electron microscope with an AMT XR 111 
camera. 
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Statistical Considerations 
Mendelian ratio significance was calculated using the Chi Square test; Kaplan-
Meier curve significance was calculated using the Log-Rank test; ECG significance was 
calculated using the two-tailed Student t test. p values are denoted in figure legends 
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CHAPTER 3.   RESULTS* 
Cardiomyopathy Induced upon Constitutive Mcl-1-deletion in Cardiac and Skeletal 
Muscle 
To define the role of MCL-1 in the heart, we have generated a constitutive muscle 
specific Mcl-1-deletion mouse model by crossing Mcl-1flox/flox mice with transgenic mice 
expressing Cre-recombinase driven by muscle creatine kinase (Ckmm) promoter that 
expresses in both skeletal and cardiac muscle starting at embryonic day 13 (E13) (Li et al. 
2000). The resulting Mcl-1flox/flox, Ckmm-Cre mice were born at the expected Mendelian 
ratio, but all pups died within the first 10 days after birth (Table 3-1 and Figure 3-1A). 
In contrast, no lethality was observed in wild-type (wt) or Mcl-1flox/wt, Ckmm-Cre mice 
(Table 3-1 and Figure 3-1A). MCL-1 protein levels were significantly decreased by 
postnatal day 1 (P1) in the heart and skeletal muscle, but not in other tissues indicating 
that the deletion of Mcl-1 in this model is efficient and muscle-specific (Figure 3-1B). 
Histological analysis of the hearts of Mcl-1flox/flox, Ckmm-Cre mice at the age of P7 
exhibited thinning of the heart walls, cardiac dilation, thrombus deposition, and 
interstitial fibrosis (Figure 3-1C). All of these features were absent in the littermate 
control mice indicating that deletion of Mcl-1 elicited the myocardial degeneration. In 
contrast to the phenotypes observed in the Mcl-1-deleted hearts, histological interrogation 
of skeletal muscle only revealed the rare appearance of sporadic myofiber necrosis and 
inflammation (Figure 3-1D). Transmission electron microscopy (TEM) analysis of Mcl-
1-deleted skeletal muscle did not detect any overt abnormalities (Figure 3-2). Therefore, 
the effects of constitutive Mcl-1-deletion were most apparent in the cardiomyocytes with 
only subtle defects observed in skeletal muscle. 
Mcl-1-deletion in Adult Cardiac Muscle Results in Rapid, Fatal Cardiomyopathy 
Since the Ckmm-Cre mice express the Cre-recombinase during embryonic 
development, it is possible that the dramatic effects on myocardium could be due to 
developmental problems rather than acute damage to mature muscle. To test this 
hypothesis, we turned to an inducible, cardiac-specific Mcl-1-deficient mouse model, in 
which Mcl-1 deletion can be induced during adulthood. We crossed Mcl-1flox/flox mice 
with Myh6-Mer-Cre-Mer (Myh-CreER) transgenic mice that express the tamoxifen-
inducible CreER-recombinase under the control of a mouse, cardiac-specific ?-myosin 
heavy chain promoter (Sohal et al. 2001). Mcl-1flox/flox, Myh-CreER mice were born at the  
-------------------- 
* Reprinted with permission from Cold Spring Harbor Laboratory Press: Wang X, 
Bathina M, Lynch J, Koss B, Calabrese C, Frase S, Schuetz JD, Rehg JE, Opferman JT. 
2013. Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction. 
Genes & development 27: 1351-1364.  
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Table 3-1. Analysis of the progeny of Ckmm-Cre-mediated deletion of Mcl-1
Mcl-1
flox/flox
, wt ? Mcl-1flox/wt, Ckmm-Cre 
Genotype P21 P1 
Expected Observed Expected Observed 
Mcl-1flox/flox, Ckmm-Cre 6 0 19 22 
Mcl-1flox/flox, wt 6 9 19 17 
Mcl-1flox/wt, Ckmm-Cre 6 8 19 17 
Mcl-1flox/wt, wt 6 7 19 20 
Total 24 24 76 76 
Chi square analysis p<0.02 p>0.05 
Ckmm-Cre deletion of Mcl-1 produces normal Mendelian ratios of newborn pups on day 
1 after birth (P1), but these mice do not survive to weaning at day 21 after birth (P21).  
Expected and observed frequency of Mcl-1 status in offspring from crosses of mice with 
the indicated genotypes. Chi square analyses results are indicated.   
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Figure 3-1. Cardiomyopathy is induced upon constitutive Mcl-1 deletion in 
cardiac and skeletal muscle 
(A) Survival of muscle-specific Mcl-1-deleted mice. (**) P < 0.01 by log-rank test when 
compared with controls. (B) Constitutive Mcl-1 deletion in heart and skeletal muscle. All 
tissues were harvested at P1 and immunoblotted with MCL-1 and Actin. (C)
Hematoxylin and eosin (H&E)-stained longitudinal sections of the heart indicate dilated 
cardiomyopathy and a loss of myofibrils. Connective tissue indicative of fibrosis stained 
blue with the Masson’s trichrome stain. Hearts were harvested at P7. Magnifications: top, 
2×; middle and bottom, 40×. (D) H&E-stained longitudinal sections of the tongue 
skeletal muscle indicate swollen fragmented fibers with hyaline necrosis. Magnification, 
40×.  
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Figure 3-2. Mcl-1-deleted skeletal muscle revealed no overt evidence of myopathy   
Transmission electron micrographs indicated relatively normal skeletal muscle fibers and 
associated mitochondria ultrastructure comparable to littermate control.  Scale bar 
represents: upper panel is 2 μm and lower panel is 500 nm.  
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expected Mendelian ratio and exhibited no observable phenotype in the absence of 
tamoxifen treatment. However, two weeks after tamoxifen treatment of adult mice (aged 
8-12 weeks), we observed a significant decrease of MCL-1 protein levels specifically in 
the hearts of Mcl-1flox/flox, Myh-CreER mice, but not littermate control mice (Mcl-1wt/wt, 
Myh-CreER) (Figure 3-3A). Three weeks after tamoxifen initiation, echocardiographic 
analysis (ECHO) detected dilated cardiomyopathy with increased left ventricle interior 
dimension (LVID), decreased left ventricle posterior wall (LVPW) and interventicular 
septum (IVS) wall thickness of cardiac specific Mcl-1-deficient mice, but not littermate 
controls including Mcl-1wt/wt, Myh-CreER mice (Figure 3-3B). These data indicate that the 
lack of contractility is due to Mcl-1 deletion and not merely due to Cre activation.  The 
left ventricle (LV) contractility as measured by ejection fraction (EF) and fraction 
shortening (FS) was significantly decreased and worsened with time after tamoxifen-
treatment (Figure 3-3C). Ultimately, the Mcl-1flox/flox, Myh-CreER mice exhibited overt 
signs of heart failure 3 weeks after tamoxifen initiation and virtually all animals 
succumbed shortly thereafter to heart failure (Figure 3-3D). In a time-course experiment, 
we observed cardiac dysfunction in Mcl-1flox/flox, Myh-CreER mice as soon as one week 
after tamoxifen administration (Figure 3-4A). Minor decreases in the cardiac function of 
Mcl-1flox/flox, Myh-CreER mice prior to tamoxifen administration were consistent with a 
low level of recombination induced by CreER leakiness (Figure 3-4B). These data 
indicate that the cardiac dysfunction induced by Mcl-1-deletion in adult mice is initiated 
quickly after deletion and rapidly leads to cardiac failure.   
Consistent with the ECHO data, histological sections of Mcl-1flox/flox, Myh-CreER
mice harvested 3 weeks after tamoxifen initiation displayed significantly dilated left 
ventricles and decreased wall thickness when compared with littermate control hearts 
(Figure 3-3E). Higher magnification histology revealed the loss of myofibrils in Mcl-1-
deleted hearts (Figure 3-3E). Furthermore, the regions with myofiber loss exhibited 
dramatic deposition of interstitial connective tissue as detected by Masson’s trichrome 
staining (Figure 3-3F). These data indicate that similar to the constitutive deletion of 
Mcl-1 in cardiac and skeletal muscle (Ckmm-Cre) that inducible deletion of Mcl-1 in 
adult cardiac tissue (Myh-CreER) results in a rapid and fatal cardiomyopathy.   
Cardiac-specific Deletion of MCL-1 Induced Cell Death 
MCL-1 is an anti-apoptotic protein, and therefore it could be predicted that loss of 
MCL-1 expression promotes the induction of apoptosis, as has been observed in a variety 
of other tissues (Opferman et al. 2003; Opferman et al. 2005; Steimer et al. 2009). Within 
1 wk after tamoxifen treatment, we observed that Mcl-1 deletion results in the loss of 
cardiomyocytes and a corresponding increase in fibrosis. To test whether cardiac-specific 
deletion of MCL-1 induces apoptosis of the cardiomyocytes, we performed terminal 
deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) and Caspase-3 
immunohistochemical staining in constitutive (Ckmm-Cre) Mcl-1-deleted hearts and 
inducible tamoxifen-treated Myh-CreER hearts. Low but significant levels of apoptosis 
were observed in Mcl-1-deleted hearts in both mouse models (Figure 3-5). These data are 
consistent with previous reports that even low levels of cell death occurring in the heart  
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Figure 3-3. Mcl-1 deletion in adult cardiac muscle results in rapid, fatal 
cardiomyopathy 
(A) Tamoxifen-induced Mcl-1 deletion in the heart. All tissues were harvested 2 wk after 
tamoxifen initiation and immunoblotted with MCL-1 and Actin. (B) Cardiac function of a 
Mcl-1-deleted heart. Transthoracic ECHO studies were performed 3 wk after tamoxifen 
initiation. M-Mode images were recorded through IVS and LVPW at the papillary 
muscle level to get the LV dimensions and IVS and LVPW thickness. (C) Contractility of 
a Mcl-1-deleted heart as measured by ECHO for LV EF and FS. The data are presented 
as percent of baseline (before tamoxifen treatment). (**) P < 0.01. The number of mice 
analyzed is indicated as n. Note: Only twoMcl-1-deleted mice were analyzed at 6 wk due 
to the death of most animals by this time point. Error bars represent the standard error of 
the mean. (D) Survival of cardiac-specific Mcl-1-deleted mice. (**) P < 0.01 by log-rank 
test. (E) H&E-stained cross sections of the heart indicate dilated cardiomyopathy and a 
loss of myofibrils. Magnifications: left, 2×; right, 40×. (F) Fibrosis in the cross-sections 
of the heart stained blue with theMasson’s trichrome stain. Magnifications: left, 2×; right, 
40×. 
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Figure 3-4. Kinetic analyses of cardiac dysfunction in Mcl-1-deleted mice 
(A) Earliest onset of cardiac dysfunction after Mcl-1-deletion. Transthoracic 
echocardiography was performed every seven days after tamoxifen initiation for 
indicated mouse strains. M-mode images were taken and left ventricle (LV) ejection 
fraction (EF) and fraction shortening (FS) were calculated. The data were presented as 
percent of baseline (before tamoxifen treatment). **p<0.01. Error bars represent the 
standard error of mean.  Control mice are a combination of Mcl-1flox/wt and Mcl-1flox/flox, 
both without Cre. (B) Leakiness of the Myh-CreER. DNA was extracted from heart tissue 
and PCR were performed. 
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Figure 3-5. Cardiac-specific deletion of MCL-1 induced cell death 
(A) Caspase-3- and Caspase-7-stained sections of the heart indicate positive cells in 
constitutively Mcl-1-deleted hearts (harvested at P7). Magnification, 40×. (B) TUNEL 
and Caspase-3 stained sections of the heart indicated positive cells in tamoxifen-induced 
Mcl-1-deleted hearts (three weeks after tamoxifen initiation). Magnification, 40×. (C)
Number of TUNEL- and Caspase-3-positive cardiomyocytes upon Mcl-1 deletion. The 
number of mice analyzed is indicated as n. Error bars represent the standard error of the 
mean. The P-values are indicated comparing wild-type with Mcl-1-deleted mice by two-
tailed Student’s t-test. 
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are sufficient to result in cardiomyopathy, as adult cardiomyocytes are limited in their 
ability to regenerate after damage. (Kirshenbaum and Schneider 1995; Wencker 2003). 
Anti-apoptotic MCL-1 functions in part by binding proapoptotic molecules, 
including BAX, BAK, BIM, PUMA, NOXA, and BID, on the mitochondria to prevent 
the induction of cell death (Certo et al. 2006; Willis et al. 2007). Immunoblot analyses of 
proapoptotic molecule expression indicated that upon Mcl-1 deletion, the expression of 
most proapoptotic effectors at the mitochondria was unchanged, but both BAX and BIM 
levels were subtly elevated in Mcl-1-deleted hearts (Figure 3-6). We were unable to 
detect significant expression of either PUMA or NOXA (data not shown), potentially as 
MCL-1 loss may be insufficient to induce the expression of these molecules in the heart, 
unlike overt stimuli like ischemia reperfusion (Toth et al. 2006). BNIP3, a molecule that 
has been implicated in cardiac cell death (Regula et al. 2002), was also found to be 
induced by Mcl-1 deletion (Figure 3-6). Therefore, Mcl-1 deletion is accompanied by an 
increase in expression of a number of proapoptotic proteins, including BAX, BIM, and 
BNIP3. 
Mitochondrial Ultrastructural Abnormalities and Respiratory Deficiency in Mcl-1-
deleted Hearts 
Adequate cardiac function is dependent on an organized myocardium and 
mitochondria (Kuznetsov and Margreiter 2009); therefore, we analyzed the ultrastructure 
of Mcl-1-deleted hearts by TEM. In normal myocardium, mitochondria containing cristae 
with high electron density are elongated and tightly aligned between myofibrils (Milner 
et al. 2000). However, mitochondria in the Mcl-1-deleted myocardium from both mouse 
models appeared rounded, disorganized, and dispersed (Figure 3-7A, B). The cristae 
structure of mitochondria also appeared frequently fragmented, disrupted, and degraded, 
and many mitochondria possessed large vacuoles within an intact OMM (Figure 3-7A, 
B). These defects were similar to those observed in the mitochondria from Mcl-1-deleted 
SV40-transformed MEFs (Perciavalle et al. 2012). Additionally, the loss of myofibrils 
detected by TEM was apparent from Mcl-1-deleted but not littermate control hearts 
(Figure 3-7A, B). 
Mitochondrial cristae are enriched with proteins of the ETC that participate in 
mitochondrial oxidative phosphorylation and respiration (Da Cruz et al. 2003). Therefore, 
we sought to address whether the mitochondria isolated from Mcl-1-deleted 
cardiomyocytes exhibited defects in respiration by measuring the oxygen consumption 
rate (OCR). The mitochondria isolated from tamoxifen-treated Mcl-1flox/flox, Myh-CreER
hearts revealed reduced state 3 respiration (ADP-stimulated) when compared with 
littermate control mitochondria. The respiratory control ratio (RCR) of the Mcl-1-deleted 
mitochondria was significantly lower than that of littermate controls (Table 3-2). 
Furthermore, the maximal respiration of Mcl-1-deleted mitochondria (FCCP-uncoupled) 
was also reduced when compared with littermate controls (Table 3-2). Last, Mcl-1
deletion caused individual ETC complex enzymatic activity for NADH ubiquinone 
oxidoreductase (complex I) and cytochrome c oxidase (complex IV) to be reduced when  
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Figure 3-6. Expression of pro-apoptotic molecules in the cardiac mitochondria 
Cardiac mitochondria were isolated from tamoxifen-treated Mcl-1wt/wt , Myh-CreER, Mcl-
1flox/flox, Myh-CreER, Myh-DKO and Myh-TKO mice and blotted with indicated 
antibodies.  Prohibitin serves as loading control. 
  
41
Figure 3-7. Mitochondrial ultrastructural abnormalities and respiratory 
deficiency in Mcl-1-deleted hearts 
Transmission electron micrographs indicate disrupted myocardium and disorganized 
mitochondria with abnormal cristae structure in (A) Constitutively Mcl-1-deleted hearts 
(harvested at P9). Bar, 500 nm. (B) Tamoxifen-induced Mcl-1-deleted hearts (3 wk after 
tamoxifen initiation).Bar, 500 nm.  
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Table 3-2. Oxygen consumption of isolated cardiac mitochondria 
Genotype Glutamate/malate 
STATE 3 STATE 4 RCR FCCP 
Mcl-1flox/wt (n=6) 400.5±29.8 94.5±7.9 4.3±0.1 408.3±27.2 
Mcl-1flox/flox, Myh-CreER (n=3) 239.9±9.7* 83.8±6.0 2.9±0.1** 236.2±7.6** 
Myh-DKO (n=3) 485.8±55.5 121.3±14.3 4.0±0.2 522.6±62.5
Myh-TKO (n=3) 287.2±4.5* 100.9±15.3 3.0±0.4** 262.7±21.1* 
Oxygen consumption of mitochondria isolated from Mcl-1flox/wt and Mcl-1flox/flox, Myh-
CreER hearts were 2 weeks after tamoxifen-treatment and from Myh-DKO and Myh-TKO 
hearts isolated 8 weeks after tamoxifen-treatment.  Glutamate (5 mM) and malate (2.5 
mM) are substrates for Complex I. State 3 respiration is stimulated by ADP (150 ?M). 
State 4 respiration is the rate after adding oligomycin (2 ?g/ml). Maximum respiration is 
the rate after adding FCCP (0.4 ?M). RCR is the ratio of state 3 and state 4. *p<0.05, 
**p<0.01 when compared to Mcl-1flox/wt mitochondria.  For each group, (n) indicates the 
number of individual animals used for mitochondrial isolation and each measurement 
was done in duplicate.  
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assessed from isolated mitochondria but did not alter the function of succinate ubiquinone 
oxidoreductase (complex II) (Figure 3-8A). The decreased function of the ETC 
components was not due to differential purification, as similar levels of mitochondrial 
(Prohibitin and MnSOD) and endoplasmic reticulum (BiP) contaminants were found in 
the preparations (Figure 3-8B). These data suggest that MCL-1 is necessary for the 
maintenance of normal cardiac mitochondrial respiration. 
Mitochondrial dysfunction can result in elevated production of ROS (Wallace 
1999). ROS are well known to induce mtDNA mutations or deletions that have been 
implicated to cause cardiomyopathy (Fosslien 2003). Therefore, we investigated whether 
we could detect alterations in the mitochondrial genome by quantitative real-time PCR 
(qPCR). Consistent with previous observations made in Mcl-1-deleted MEFs and livers 
(Perciavalle et al. 2012), the induction of cardiac-specific Mcl-1 deletion resulted in 
decreased mtDNA levels when normalized to genomic DNA (Table 3-3). Given the drop 
in mtDNA, we analyzed whether reductions in the total mitochondria number in the 
deleted hearts could be detected. Importantly, we did not observe major differences in the 
total amount of mitochondrial proteins or citrate synthase enzymatic activity in Mcl-1-
deleted and littermate control hearts, indicating that the loss of MCL-1 did not simply 
lead to a dramatic loss of total mitochondrial mass (Figure 3-8B, C). Furthermore, there 
was no detectable induction of a PGC1-?-dependent mitochondrial biogenesis program in 
the Mcl-1-deleted hearts; instead, PGC1-? target genes were actually repressed (Figure 
3-9). Such a repression of PGC1-? target genes has also been observed in several models 
of cardiac hypertrophy and failure (Lehman and Kelly 2002; Garnier et al. 2003; Arany et 
al. 2006). Thus, these data indicate that Mcl-1 deletion results in mitochondrial 
dysfunction, which we predict contributes to the cardiomyopathy and decreased 
mitochondrial respiration in our model. 
Genetic Ablation of Bax and Bak Improves Cardiac Function and Survival of 
Cardiac-specific Mcl-1-deletion 
To further confirm that apoptosis contributed to the cardiac pathology after Mcl-1
deletion, we sought to genetically disable the intrinsic apoptotic pathway in the mouse 
heart by deleting both proapoptotic effectors BAX and BAK (Lindsten et al. 2000; Wei et 
al. 2001). To do so, Mcl-1flox/flox mice were bred to Baxflox/flox, Bak-deficient mice to 
produce mice in which Mcl-1, Bax, and Bak could simultaneously be genetically deleted 
using either Ckmm-Cre or, Myh-CreER (Takeuchi et al. 2005). In addition, deletion of Bax
and Bak may also down-regulate cell death caused by primary necrosis (opening of 
mPTP in the absence of cytochrome c release) by increasing the threshold for the opening 
of the mPTP (Whelan et al. 2012). Therefore, loss of BAX and BAK could be anticipated 
to block both necrotic and apoptotic cell death. 
Mcl-1flox/flox, Baxflox/flox, Bak-/-, Ckmm-Cre (hereafter referred to as Ckmm triple 
knockout [TKO]) mice were born at the expected Mendelian ratios and, unlike Mcl-
1flox/flox, Ckmm-Cre, were able to survive to adulthood (Figure 3-10A). Analysis of the 
one mouse out of 10 Ckmm-TKO mice that revealed cardiac dysfunction at 5 wk of age  
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Figure 3-8. Enzymatic function of Mcl-1-deleted mitochondria 
(A) Enzymatic activity assays for indicated electron transport chain components for 
mouse cardiac mitochondria isolated from Mcl-1wt/wt, Myh-CreER, Mcl-1flox/flox, Myh-
CreER, Myh-DKO and Myh-TKO mice after tamoxifen treatment. Error bars represent the 
standard error of mean. (B) Purity of the isolated cardiac mitochondria was indicated by 
mitochondria marker Prohibitin and MnSOD. BIP serves as ER marker. (C) Citrate 
synthase activity in whole heart homogenates from Mcl-1wt/wt, Myh-CreER and Mcl-
1flox/flox, Myh-CreER mice after tamoxifen treatment. Error bars represent the standard 
error of mean. 
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Table 3-3. Quantification of mitochondrial DNA from isolated cardiac muscle 
Genetype Fold Change vs. Mcl-1flox/wt, (wt) no Cre 
Mcl-1flox/wt, wt (n=5) 1 
Mcl-1flox/flox, Myh-CreER (n=4) 0.75±0.086 
Myh-DKO (n=3) 0.97±0.192 
Myh-TKO (n=2) 0.82±0.01 
Cardiac muscle fiber was isolated after tamoxifen-treatment and assessed for relative 
mitochondrial DNA and genomic DNA.  The Mcl-1flox/wt and Mcl-1flox/flox, Myh-CreER
hearts were harvested 2 weeks after tamoxifen-treatment while the Myh-DKO and Myh-
TKO hearts were harvested 8 weeks after tamoxifen-treatment.  The ratio of mtDNA and 
nDNA by quantitative real-time PCR is presented with the error representing the standard 
error of the mean.  For each group, (n) indicates the number of individual animals used 
for DNA isolation and each measurement was done in triplicate.
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Figure 3-9. mRNA level of PGC1-alpha and its target genes 
Tfam gene encodes a mitochondrial transcription factor that is a key activator for 
mitochondrial genome transcription. Cpt1b and Macd genes encode enzymes involved in 
the fatty acid ?-oxidation. Cox5b, Cox4i, cyt c and Atp synthase F1 genes encode proteins 
of the electron transport chain. Catalase, Sod1 and Sod2 genes encode antioxidative 
proteins. RNA was extracted from heart tissue of mice by TRIzol (Ambion) and reverse 
transcribed by using SuperScript III first-strand synthesis system (Invitrogen). Real-time 
PCR with SYBR green (Bio-Rad) detection was performed using a BioRad icycler. ddCt 
method was used to calculate the mRNA level. The assay was done in triplicate for each 
sample. *p<0.05, **p<0.01 as determined by two-tailed Student t test. Error bars 
represent the standard error of mean. 
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Figure 3-10. Genetic ablation of Bax and Bak improves cardiac function and 
survival of constitutive cardiac-specific Mcl-1 deletion 
(A) Survival of Ckmm-TKO mice and littermate control mice. (**) P < 0.01 by log-rank 
test when compared with Mcl-1flox/flox, Ckmm-Cre mice. (B) Contractility of Mcl-1wt/wt, 
Mcl-1flox/flox Baxflox/wt Bak+/- Ckmm-Cre, Ckmm-DKO, and Ckmm-TKO hearts. The data 
are presented as percent of baseline (before tamoxifen treatment). (*) P < 0.05 versus 
littermate control mice. Error bars represent the standard error of the mean. (C) H&E 
stained cross-sections of the heart indicate dilated cardiomyopathy and a loss of 
myofibrils, and Masson’s trichrome staining indicates fibrosis in the Mcl-1flox/flox
Baxflox/wt Bak+/- Ckmm-Cre heart. Magnifications are indicated for each panel. All hearts 
were harvested at P84.  
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and subsequently died indicated that this mouse exhibited incomplete Bax deletion 
(Figure 3-10A). ECHO analysis was unable to detect significant cardiac dysfunction in 
the other Ckmm-TKO mice as compared with wild-type and Baxflox/flox, Bak-/-, Ckmm-Cre 
(hereafter referred to as Ckmm double knockout [DKO]) littermates up to 10 wk of age 
(Figure 3-11B). Surprisingly, even Mcl-1flox/flox, Baxflox/flox, Bak+/-, Ckmm-Cre (expressing 
fewer Bax and Bak alleles) had an extended life span when compared with Mcl-1flox/flox, 
Ckmm-Cre but still exhibited impaired cardiac contractility and eventually succumbed 
(Figs. 3-10A, B). Histology of Ckmm-TKO revealed that the cardiomyopathy observed in 
Mcl-1flox/flox, Ckmm-Cre mice was alleviated (Figure 3-10C). In contrast, Mcl-1flox/flox, 
Baxflox/flox, Bak+/-, Ckmm-Cre mice still exhibited loss of cardiac myofibers and interstitial 
fibrosis (Figure 3-10C). These results indicate that the more Bax and Bak alleles 
remaining, the more severe the cardiac phenotype observed upon Mcl-1 deletion, 
suggesting that the pro-apoptotic effectors play an important role in the pathogenesis of 
cardiomyopathy induced by Mcl-1 deletion. 
To test whether inhibition of apoptosis was capable of abrogating the cardiac 
damage due to inducible Mcl-1 deletion in adult hearts, we generated inducible cardiac- 
specific Mcl-1flox/flox, Baxflox/flox, Bak-/-, Myh-CreER (hereafter referred to as Myh-TKO) 
mice by crossing Mcl-1flox/flox, Myh-CreER mice with Baxflox/flox, Bak-/- mice. Immunoblot 
analyses indicated efficient deletion of MCL-1, BAX, and BAK in cardiac tissue of 
tamoxifen-treated Myh-TKO mice (Figure 3-11A). In contrast to the prevalent mortality 
observed in Mcl-1flox/flox, Myh-CreER mice 3 wk after tamoxifen initiation, Myh-TKO 
mice were able to survive for >8 wk after the induction of Cre, at which point they were 
sacrificed for analysis (Figure 3-11B). During the first week after tamoxifen treatment, 
Myh- TKO mice exhibited a transient but significant defect in both EF and FS that 
eventually resolved (Figure 3-11C). Upon sacrifice, Myh-TKO hearts were comparable 
with littermate control Mcl-1flox/wt hearts without the appearance of overt apoptosis, 
interstitial fibrosis, and loss of myofibers observed in Mcl-1flox/flox, Myh-CreER hearts 
(Figure 3-2E, F; Figure 3-11D; Figure 3-5B, C). We also observed the induction of 
BIM and BNIP3 in the Myh-TKO hearts, indicating that they are upstream of BAX and 
BAK (Figure 3-6). Therefore, co-deletion of BAX, BAK, and MCL-1 prevents heart 
failure and overt cardiomyopathy by blocking cell death. 
Genetic Ablation of Bax and Bak Is Insufficient to Restore Mitochondrial 
Abnormalities Induced by Mcl-1-deletion 
Although ECHO and histological analyses did not display significant cardiac 
dysfunction, analyses of the ultrastructure of TKO hearts by TEM revealed that the 
myocardial organization and mitochondrial ultrastructure were quite heterogeneous 
among different regions of the heart (Figure 3-12). Examination indicated that both 
interfibrillar and subsarcolemmal mitochondria appear equally affected and that the 
mitochondria with abnormal ultrastructure were primarily found in the endocardium and 
not the epicardium. Both Ckmm-TKO and Myh-TKO hearts still exhibited regions of 
rounded mitochondria that were disorganized and dispersed (Figure 3-13). The cristae 
structure of the damaged Ckmm-TKO and Myh-TKO mitochondria were fragmented and  
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Figure 3-11. Genetic ablation of Bax and Bak improves cardiac function and 
survival of inducible cardiac-specific Mcl-1 deletion 
(A) Tamoxifen induced Mcl-1, Bax, and Bak deletion in heart. All tissues were harvested 
8 wk after tamoxifen initiation and immunoblotted with MCL-1, BAX, and BAK. 
MnSOD served as the mitochondrial marker and Actin served as the loading control. (B)
Survival of Myh-TKO mice and littermate controls. (**) P < 0.01 as determined by log-
rank test when compared with Mcl- 1flox/flox Myh-CreER. (C) Contractility of Mcl-
1wt/wt, Mcl-1flox/flox Myh-CreER, Myh-DKO, and Myh-TKO hearts. The data are presented 
as percent of baseline (before tamoxifen treatment). (*) P < 0.05; (**) P < 0.01. Error 
bars represent the standard error of the mean. (D) H&E-stained cross-sections of the heart 
indicate no evidence of cardiomyopathy in the Myh-TKO hearts. Masson’s staining 
indicates no evidence of fibrosis in Myh-TKO hearts. All hearts were harvested 8 wk 
after tamoxifen initiation. Magnifications are as indicated.   
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Figure 3-12. Genetic ablation of Bax and Bak is insufficient to obviate 
mitochondrial abnormalities induced by Mcl-1-deletion 
Low magnification transmission electron micrographs indicated disrupted myocardium, 
mitochondria with abnormal cristae structure in (A) Constitutively Mcl-1-deleted Ckmm-
TKO hearts (harvested at P84), (B) tamoxifen induced Mcl-1-deleted Myh-TKO hearts 
(eight weeks after tamoxifen initiation).  The scale bars represent 2 μm.
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Figure 3-13. Mitochondrial ultrastructural abnormalities in Mcl-1-deleted hearts 
cannot be prevented by genetic ablation of Bax and Bak
Transmission electron micrographs indicate disrupted myocardium and disorganized 
mitochondria with abnormal cristae structure in (A) Constitutively Mcl-1-deleted Ckmm-
TKO hearts (harvested at P84). (B) Tamoxifen induced Mcl-1-deleted Myh-TKO hearts 
(8 wk after tamoxifen initiation). For the Ckmm-TKO and Myh-TKO samples, regions 
with relatively normal morphology are indicated by i and iii, whereas the regions with 
abnormal ultrastructure are indicated by ii and iv. Bars: top panels (lower magnification), 
2 mm; bottom panels (higher magnification), 500 nm.
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degraded but possessed intact OMMs (Figure 3-13). These defects were similar to those 
observed in the mitochondria from Mcl-1-deleted myocardium (Figure 3-7A, B). 
Additionally, TEM analyses of Ckmm-TKO and Myh-TKO hearts still revealed 
myocardial regions that featured some loss of myofibrils, but not to the same extent as 
those occurring in Mcl-1-deleted hearts (Figure 3-7A, B). 
Since the TEM detected that Myh-TKO hearts still exhibit defective mitochondria, 
we tested whether Myh-TKO-isolated mitochondria displayed detectable respiratory 
deficiencies. To this aim, Myh-TKO, Myh-DKO, and Mcl-1-deleted cardiac mitochondria 
were isolated, and their ability to respire was determined by measuring OCR. As 
previously determined, mitochondria from Mcl-1-deleted hearts displayed decreased 
OCR (Table 3-2). In contrast, Myh-DKO mitochondria respired similarly to control 
mitochondria, indicating that loss of both BAX and BAK does not result in defective 
mitochondrial respiration (Table 3-2). However, despite mitigating the symptoms of Mcl-
1 deletion, the mitochondria from Myh-TKO mice still exhibited defective OCR, 
indicating a respiratory defect (Table 3-2). These data suggest that MCL-1 may also play 
a role in promoting normal cardiac mitochondrial respiration that is distinct from its 
ability to inhibit apoptosis. 
The mitochondrial respiratory defects induced by cardiac-specific Mcl-1 deletion 
alone led to the loss of mtDNA (Table 3-3). Therefore, we investigated whether the loss 
of mtDNA could be alleviated in the Myh-TKO hearts. Unlike Myh-DKO cardiac tissue, 
which expressed similar levels of mtDNA when compared with nondeleted littermate 
control hearts, the hearts from Myh-TKO mice still displayed the loss of mtDNA (Table 
3-3). Taken together, these data indicate that even when apoptosis is genetically blocked 
by loss of BAX and BAK, the loss of MCL-1 expression in cardiac tissue results in 
mitochondrial dysfunction. 
Mcl-1-loss in Cardiomyocytes Impairs Autophagy Induction While Co-deletion of 
Mcl-1, Bax, and Bak Restores Cardiac Autophagy 
Autophagy and the ubiquitin-proteasome system are responsible to the efficient 
degradation of cytoplasmic proteins and dysfunctional organelles by sequestration within 
an autophagosome that fuses to lysosomes for degradation (Levine and Klionsky 2004). 
In cardiomyocytes, basal autophagy is indispensable to maintain normal cardiac function 
under baseline condition (Nakai et al. 2007); however, the adaptive role of autophagy 
under cardiac stress is still under debate dependent upon the genetic model (Nakai et al. 
2007; Zhu et al. 2007). In our model, we observe that Mcl-1-deleted hearts exhibit 
reduced LC3II/LC3I ratios, elevated p62 levels, and deposition of ubiquitinylated 
aggregate, indicating an inhibition of autophagy (Figure 3-14). In contrast, the Myh-TKO 
hearts reveal a robust elevation of LC3II/LC3I ratios, reduced p62 levels, and diminished 
ubiquitin aggregates in the heart (Figure 3-14). Therefore, the loss of BAX and BAK in 
the context of MCL-1 deficiency restores normal induction of autophagy. 
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Figure 3-14. Mcl-1-loss in cardiomyocytes impairs autophagy induction while co-
deletion of Mcl-1, Bax, and Bak restores cardiac autophagy 
(A) Immunoblot analyses of hearts isolated from indicated genotypes at 3 weeks after 
tamoxifen administration. Autophagy markers LC3II/I and p62 are shown. Efficiency of 
Cre-deletion is indicated by MCL-1 protein and ATP5A1 serves as loading control. Each 
lane represents a separate mouse. (B) Quantitation analyses of LC3II/LC3I, p62, and total 
LC3 levels. Error bars represent the standard error of the mean. (C) Ubiquitin 
immunohistochemistry from longitudinal heart sections from Mcl-1wtwt Myh-CreER, Mcl-
1flox/flox Myh-CreER, Myh-DKO and Myh-TKO mice (3 weeks after tamoxifen-
administration). Red staining in Mcl-1flox/flox Myh-CreER heart section indicates ubiquitin 
aggregates in cardiomyocytes. Magnification, 64×.
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CHAPTER 4.   DISCUSSION  
Role of MCL-1 in the Heart Homeostasis and Heart Disease Treatment 
Genetic ablation of MCL-1 in a myriad of cellular lineages leads to cell 
autonomous deficiencies, indicating that MCL-1 is a unique pro-survival BCL-2 family 
member (Opferman et al. 2003; Opferman et al. 2005; Arbour et al. 2008; Steimer et al. 
2009). The Opferman laboratory has revealed that besides its classical anti-apoptotic 
aspect, MCL-1 also facilitates mitochondrial physiology in vitro, and these two distinct 
functions are dependent upon the sub-mitochondrial localizations of MCL-1 (Perciavalle 
et al. 2012). Therefore, it will be important to delineate the contributions of MCL-1’s 
dual functions in an in vivo system. Because the heart is particularly sensitive to death 
stimuli and highly dependent upon mitochondrial function, it is ideal for the study of 
MCL-1’s dual functions. Moreover, the role of MCL-1 in heart homeostasis has not been 
determined yet. 
BCL-2 Family Members and Cardiomyocyte Death 
Since cardiomyocytes lack the ability to regenerate and repair, they have 
developed several strategies to minimize cell death in the heart (Wencker 2003). It is 
reported that cardiomyocytes possess low level of APAF-1, and microinjection of 
cytochrome c into them is insufficient to induce cell death (Potts et al. 2005). However, 
increased apoptotic cell death has still been implicated in various heart diseases such as 
myocardial infarction, ischemia/reperfusion injury, cardiomyopathy and heart failure 
(Narula et al. 1996; Olivetti et al. 1997; Saraste et al. 1997).  
BCL-2 family members are pivotal for the regulation of cell death; therefore their 
roles in cardiomyocyte death have been intensively studied over the past decades. Under 
steady state, genetic ablation of either Bcl-2 or Bcl-XL revealed no overt cardiovascular 
abnormalities (Veis et al. 1993; Motoyama et al. 1995; Fernandez et al. 2001). However, 
those anti-apoptotic proteins have been revealed to be protective for cardiomyocytes 
under various stresses. For example, endogenous BCL-2 and BCL-XL level decline 
during the ischemia/reperfusion injury.  In contrast, overexpression of BCL-2 or BCL-XL 
blocks apoptosis and results in smaller infarcts, improved cardiac function and survival 
(Brocheriou et al. 2000; Chen et al. 2001; Imahashi et al. 2004). Moreover, transgenic 
expression of BCL-2 can attenuate cardiomyopathies by inhibiting apoptotic cell death 
(Milner et al. 2000; Weisleder et al. 2004; Maloyan et al. 2010). A variety of pro-
apoptotic BH3-only family members, including BID, PUMA, BAD, BNIP3, and NIX 
have been reported to be induced upon cardiac stress and are implicated in the 
pathogenesis of the disease (Murriel et al. 2004; Galvez et al. 2006; Toth et al. 2006; 
Diwan et al. 2008). Ablation of pro-apoptotic effector Bax has been shown to be 
protective against ischemia/reperfusion injury (Hochhauser et al. 2003). These data 
indicate that while both pro- and anti-apoptotic BCL-2 family members clearly play 
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important roles in modulating the response of cardiomyocyte death to various stresses, 
the specific genetic regulators have remained unknown.  
MCL-1 Is an Essential Pro-survival Regulator for Heart Homeostasis 
Our data demonstrated that cardiac-specific deletion of anti-apoptotic Mcl-1 leads 
to a fatal dilated cardiomyopathy under steady state exhibiting cardiomyocytes loss, 
ultrastructural abnormalities in both myocardium and associated mitochondria, and 
impaired mitochondrial respiration. The number of apoptotic cardiomyocytes was 
elevated in the Mcl-1-deleted heart. Similar outcomes were observed either when Mcl-1
was deleted by Ckmm-Cre initiating at E13 or when Mcl-1 is deleted during adulthood by 
tamoxifen-inducible Myh-CREER.   
The development of the heart starts at E7.5, beating heart tube can be observed at 
E8.5, and the primary four cardiac chambers is formed by E10.5 (Xin et al. 2013). 
Apoptosis is a normal and necessary phenomenon for embryonic heart development as it 
is involved in the developmental remodeling of the organ, and has been reported to be 
essential for ventricular morphogenesis from E11-E16 (Abdelwahid et al. 1999). After 
birth, apoptosis still plays an important role in the ventricular structural remodeling of the 
postnatal heart (Fernandez et al. 2001). Prior to birth, fetal blood is oxygenated by 
placenta and enters the right ventricle. Immediately after birth, the neonatal lung expands 
upon the first breath and establishes pulmonary circulation, resulting in a drop in the 
pressure load on the right ventricle and an increase in the pressure load on the left 
ventricle. This mechanical change induces a proliferative response in the left ventricle, 
and an apoptotic response in the right ventricle, which results in the final structure of the 
mature and functional heart. Therefore, the excessive apoptosis in the heart induced upon 
Mcl-1 deletion during the embryonic stage could impair the embryonic heart 
development and postnatal cardiac remodeling, leading to cardiac dysfunction and heart 
failure. 
Apoptotic cell death in neonatal heart starts to diminish at P4.5 and then maintains 
at a very low level throughout the adulthood (Fernandez et al. 2001). When Mcl-1 was 
deleted in adult hearts, we observed that the apoptotic rate reached 2~3%, which was 
significantly higher than wild-type heart, and sufficient to cause cardiomyopathy, heart 
failure and final death. After P7, the heart lost the regenerative ability and cardiomyocyte 
loss can only be repaired by connective tissue regeneration (Porrello et al. 2011). As a 
result, intensive interstitial fibrosis is observed in Mcl-1-deleted heart. 
Anti-apoptotic MCL-1 interacts with pro-apoptotic proteins to prevent the 
induction of cell death. It can either bind to BH3-only proteins to prevent them from 
activating BAX and BAK, or directly interact with BAX and BAK, blocking the MOMP 
and the release of apoptogenic proteins from IMS (Thomas et al. 2013). Since Mcl-1
deletion induced cardiomyocyte apoptosis accompanied by an increase in expression of 
pro-apoptotic proteins, including BIM, BNIP3 and BAX; it is not surprising to observe 
that co-deletion of Bax and Bak, the essential intrinsic apoptotic effectors (Lindsten et al. 
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2000), could substantially rescue the dilated cardiomyopathy and lethality upon Mcl-1
deletion.  
Moreover, BAX can also regulate necrotic cell death by increasing the threshold 
for the opening of the mPTP, which is independent of its pro-apoptotic function (Whelan 
et al. 2012). In the myocardial infarction model, deletion of Bax and Bak significantly 
reduced the infarct size, and no additional rescue effect was observed by further deletion 
of Cyclophilin-D over the Bax and Bak-deficient background, suggesting that BAX and 
Cyclophilin-D are redundant in preventing ischemia-induced necrosis. Thus, it is 
reasonable to postulate that co-deletion of Bax and Bak in the MCL-1-deficient 
background can not only block apoptosis, but also prevent necrosis. Indeed, in the 
Thomas et al. publication (Thomas et al. 2013), co-deletion of Cyclophilin-D, the key 
component of the mPTP, along with Mcl-1 in mouse hearts attenuates, but does not 
completely alleviate cardiac dysfunction and lethality, indicating that inhibiting necrotic 
death only partially rescues the cardiac dysfunction caused by Mcl-1-deletion. In contrast, 
co-deletion of Mcl-1, Bax, and Bak in mouse hearts more completely rescued the lethality 
of the cardiac dysfunction caused by Mcl-1-deletion, suggesting that while loss of Mcl-1
may induce mPTP-dependent necrosis, the induction of Caspase-3 induced by Mcl-1
deletion indicates that cytochrome c is being released, thereby triggering apoptosis. Both 
of apoptosis and necrosis can be alleviated by deletion of Bax and Bak. Therefore, the 
critical role for MCL-1 in cardiomyocytes is to prevent the induction of cell death. 
We also identified that deletion of Mcl-1 impairs autophagy induction in the 
myocardium. This was unexpected since the anti-apoptotic BCL-2 family members have 
been reported to interact with Beclin-1, an essential protein for autophagosome 
formation, to inhibit autophagy (Pattingre et al. 2005; Maiuri et al. 2007). Also, genetic 
ablation of Mcl-1 in the nervous system has been revealed to induce autophagy (Germain 
et al. 2011). Autophagy is a conserved process to clear damaged organelles and proteins, 
provide nutrients to stressed cells. Particularly, autophagy has been shown to be 
important for the heart homeostasis under steady status (Nakai et al. 2007). Therefore, the 
inhibition of autophagy in the Mcl-1-deleted heart may lead to the accumulation of mal-
functional proteins (such as p62) and damaged organelles (such as mitochondria), which 
could contribute to the development of cardiac dysfunction. 
The cross talk between apoptosis and autophagy has been reported. For example, 
Caspase-3, -7 and -8 can cleave Beclin-1 and class III phosphatidyl inositol-3-kinase 
(PI3KC3), two components of the autophagy-inducing complex, to inhibit autophagy. 
And the C-terminal cleavage product of Beclin-1 can amplify the mitochondria-mediated 
apoptosis in response to nutrient deprivation (Wirawan et al. 2010). Indeed, in the 
Thomas et al. publication, the protein level of Beclin-1 is decreased in the Mcl-1-deleted 
heart (Thomas et al. 2013).  The autophagy-related protein, Atg5, has also been reported 
to be cleaved by Calpain during apoptosis, and the truncated product can interact with 
BCL-2 proteins to facilitate apoptosis (Yousefi et al. 2006). Since apoptosis is induced in 
the MCL-1-deficient heart, this could explain the observed autophagy inhibition in our 
model. Conversely, a previous study has demonstrated that autophagy could be induced 
when apoptosis is inhibited. When Bax and Bak double-knock MEFs are treated with 
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apoptotic stimuli such as etoposide, they fail to undergo apoptosis but reveal induction in 
autophagy followed by delayed cell death, and can be alleviated by knocking-down 
Beclin-1 or Atg5 (DiMauro and Schon 2003). Therefore, in our model, when the intrinsic 
cell death pathway is blocked by co-deletion of Bax and Bak, it is possible that the 
mitochondrial dysfunction induced by Mcl-1 loss produces mitochondrial stress that 
drives autophagy in an attempt to alleviate the damage. The mechanism for how MCL-1 
regulates autophagy induction in the heart is still unclear, and will be an important topic 
of future research.   
Interestingly, no overt defects in the skeletal muscle were observed upon Ckmm-
Cre-mediated ablation of Mcl-1. There were low levels of muscle fiber necrosis, but no 
gross muscular abnormalities observable even in the skeletal muscle of Ckmm-TKO 
mice. One possibility is that skeletal muscle, which possesses the ability to regenerate, 
may be able to functionally compensate for tissue damage unlike cardiac muscle (Ciciliot 
and Schiaffino 2010). Additionally, it is possible that the skeletal muscle will not reveal 
defects until the muscle is stressed. For example, exercise-induced oxidative stress has 
been reported to reveal myopathy phenotype in a mouse model without spontaneous 
skeletal muscle disorder (Powers and Jackson 2008; Rederstorff et al. 2011). Conversely, 
MCL-1 function in the skeletal muscle may not be as important as that of cardiac muscle 
due to compensation by other family members (Dominov et al. 2001; Schwartz 2008).  
Further work will be necessary to fully realize why skeletal muscle appears to be less 
affected by Mcl-1-deletion.    
MCL-1 and Cardiac Mitochondria Physiology 
In the Mcl-1-deleted hearts, we observed massive damage in mitochondrial cristae 
structure, which is quite similar to what has been revealed in the MCL-1-deficient SV40 
transformed MEFs and liver (Perciavalle et al. 2012). Mcl-1-deleted hearts possess less 
coupled mitochondria with impaired respiration, indicating decreased ATP production 
since mitochondrial respiration is coupled with ADP phosphorylation. In addition, the 
heart is among the most mitochondrial-rich organs, and mitochondrial-generated ROS is 
the major factor in oxidative stress to the heart (Dorn and Scorrano 2010). Dysfunctional 
mitochondria can cause elevated production of ROS and ROS can cause mtDNA damage 
and inactivate iron-sulfur center containing enzymes on ETC (Esposito et al. 1999). 
Consistently, cardiac-specific deletion of Mcl-1 leads to decreased mtDNA content, and 
reduced enzymatic activity of ETC complex I and IV, but not complex II. This kind of 
change is usually observed in cases of respiratory dysfunction due to mtDNA defects, 
because complex II activity is solely dependent upon nuclear genome, while subunits of 
complex I and complex IV are encoded by mitochondrial genome (DiMauro and Schon 
2003; Chen et al. 2010). Therefore, MCL-1 is necessary for the maintenance of 
mitochondrial morphology and physiology. 
Since we deleted full-length MCL-1 in our mouse model, it could be possible that 
the observed mitochondrial dysfunction is secondary to the primary cell death due to 
ablation of the anti-apoptotic MCL-1. Co-deletion of Bax and Bak in the MCL-1-
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deficient background enables us to rule out this possibility and only observe the 
mitochondrial aspect of MCL-1. Despite grossly rescuing cardiac function and mouse 
survival, mice lacking Mcl-1, Bax, and Bak in the heart still exhibit cardiac lesions and 
defects in mitochondrial function, as evidenced by deficient mitochondrial respiration 
and the loss of mtDNA. These data suggest that MCL-1 plays an important role beyond 
simply inhibiting cell death in the heart. Because cardiac function is highly dependent 
upon mitochondrial bioenergetics, MCL-1 may be important for the long-term cardiac 
homeostasis under both steady and stressed states. Further study on the TKO mice would 
be necessary to reveal the cardiac phenotypes in response to stress. 
We have demonstrated in model cell lines and liver mitochondria that different 
forms of MCL-1 reside in distinct mitochondrial localizations where they exhibit 
separable functions (Perciavalle et al. 2012). Briefly, the OMM-localized MCL-1 
possesses pro-survival function by interacting with pro-apoptotic proteins to prevent cell 
death. In contrast, the matrix-localized MCL-1 does not inhibit cell death, but instead 
promotes mitochondrial physiology. The matrix-localized MCL-1 facilitates 
mitochondrial cristae structure to maintain normal mitochondrial morphology, IMM 
fusion, mitochondrial OXPHOS, and mitochondrial supercomplexes assembly. While the 
separation of these roles has been observed in vitro, they have not yet been shown to be 
relevant in vivo. In the heart, MCL-1 is present both on the OMM and within the 
mitochondrial matrix (Figure 4-1). Therefore it is possible that in cardiomyocytes that 
both localizations of MCL-1 may be necessary for maintaining cardiac function.  Further 
work will be necessary to functionally reconstitute cardiomyocytes of Mcl-1-deleted mice 
with individual MCL-1 mutants to test functionally the contribution of MCL-1’s anti-
apoptotic function and its ability to promote mitochondrial function. 
MCL-1 in Therapy of Heart Disease 
Our observations indicate that MCL-1 may promote cardiac function by both 
inhibiting cell death and maintain mitochondrial morphology and respiration. Other pro-
survival BCL-2 family members, such as BCL-2 and BCL-XL, have been shown to be 
protective to the heart mainly in response to stresses, whereas MCL-1 is essential for the 
survival of the cardiomyocytes at steady state. Therefore, MCL-1 is a promising target 
for cardiac disease treatment and we would predict that strategies aimed at enhancing or 
maintaining MCL-1 function in cardiomyocytes may form the basis to improve heart 
function after acute and chronic cardiac stress or damage. The development of gene 
transfer vectors and delivery systems give us the tools to specifically express MCL-1 in 
cardiomyocytes to enhance its function. Viral vectors, such as retroviruses, adenoviruses, 
and adeno-associated viruses, are commonly used to transfer genes to cardiomyocytes 
(Wolfram and Donahue 2013). 
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Figure 4-1. MCL-1 resides in different submitochondrial localizations in the heart 
The heavy membrane (HM) fraction is isolated from heart. Proteinase K  (PK) digests 
exposed proteins, osmotic shock (OS) disrupts OMM, and detergent (SDS) solubilizes 
both inner and outer mitochondrial membranes. Lysates are resolved and subjected to 
immunoblot analysis. Markers for OMM, inner membrane space (IMS), and matrix are 
indicated. 
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MCL-1 as a Target for Cancer Therapy 
Malignant cells need to acquire resistance to mitochondrial-mediated apoptosis 
and undergo metabolic alteration to support the initiation and progression of cancer 
(Kroemer 2006). MCL-1 is a unique BCL-2 family member as it can block cell death and 
promote mitochondrial physiology. Moreover, MCL-1 is one of the most amplified genes 
found in 26 human cancers (Beroukhim et al. 2010). Its overexpression is often 
associated with chemotherapeutic resistance in many different cancers including ALL, 
AML, CML, CLL, and multiple myeloma (Kaufmann et al. 1998; Wei et al. 2006; Pepper 
et al. 2008). Therefore, MCL-1 is an attractive target for cancer treatment.  
Targeting MCL-1 as a Pro-survival Protein 
Apoptosis is essential for development and homeostasis maintenance; however, 
dysregulation of apoptosis can lead to variety of pathologies including cancer. Cancer 
cells must overcome apoptotic stresses either by inducing anti-apoptotic molecules or by 
reducing the pro-apoptotic factors (Hanahan and Weinberg 2011). In the intrinsic 
apoptosis pathway, death signals trigger the activation of pro-apoptotic BH3-only BCL-2 
family members, inducing the activation of pro-apoptotic effectors BAX and BAK, 
facilitating the release of apoptosis inducing proteins to activate caspases cascade 
(Opferman 2008). Anti-apoptotic BCL-2 family members, including BCL-2, BCL-XL, 
BCL-w, MCL-1 and BFL-1/A1, interact with pro-apoptotic BCL-2 family members to 
block cell death, and are often upregulated in malignant cells as a mechanism for tumor 
initiation, progression and therapeutic resistance. As a result, there has been an increasing 
interest in developing anti-apoptotic BCL-2 family inhibitors as a strategy for cancer 
therapy. 
ABT-737/263 (navitoclax), a promising BH3 mimetic anticancer drug, has high 
affinity for BCL-2, BCL-XL, and BCL-w (Fernandez et al. 2001; Poelmann and 
Gittenberger-de Groot 2005; Xin et al. 2013), and has been shown to cause the regression 
of some tumors in mouse xenograft model (Oltersdorf et al. 2005). However, its efficacy 
as a single agent is limited for MCL-1 overexpressed tumors. Strategies using cyclin-
dependent inhibitors or tyrosine-kinase inhibitors to reduce MCL-1 levels through 
inhibition of its transcription or translation have been demonstrated to be able to sensitize 
resistant cancer cells to apoptotic cell death (Konopleva et al. 2006; van Delft et al. 2006; 
Koss et al. 2013). These kinase inhibitors may have global effects for cells and tissues, 
which could lead to side effects to render their systemic usage. Therefore, developing 
MCL-1 specific inhibitors is a more attractive therapeutic strategy and has been 
intensively explored in clinical researches.  
Targeting MCL-1 in Mitochondrial Physiology 
The role of MCL-1 in promoting mitochondrial physiology provides another clue 
for targeting MCL-1 in cancer therapy. Cancer cells constitutively upregulate aerobic 
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glycolysis. This phenomenon was described by Nobel laureate Otto Heinrich Warburg in 
1920s and termed as the “ Warburg effect ” thereafter (Otto Warburg 1927). This high 
rate of glucose uptake is the basis for using 18F-2-deoxyglucose (FDG) to differentiate 
between normal and solid tumor tissue in positron emission tomography (Lin 2011). In 
fact, the glucose transporters are often found overexpressed in cancer cells since transport 
of glucose across the plasma membrane is the first rate-limiting step of glucose 
metabolism (Macheda et al. 2005). In cancer cells, increased glucose uptake is usually 
accompanied by a decreased mitochondrial OXPHOS and biogenesis (Scatena 2012) due 
to the accumulation of defects in mitochondrial genome. The mtDNA mutations for ETC 
complex I, III, IV, and V have been reported in a variety of cancers and shown to be 
related to neoplastic transformation (Brandon et al. 2006). In addition, mutations in 
nDNA-encoding mitochondrial enzymes, including succinate dehydrogenase, fumarate 
dehydrogenase, and isocitrate dehydrogenase, have also been reported in various 
malignant diseases (Ward et al. 2010; Bardella et al. 2011; Picaud et al. 2011). These 
mutations either inhibit oxidative phosphorylation, increase the production of ROS as a 
mitogen and promote tumor cell proliferation, or permit tumors to adapt to new 
microenvironments, especially during tumor progression and metastasis (Brandon et al. 
2006). Accordingly, inhibition of mitochondrial function of MCL-1 may be beneficial for 
the malignant progression and thus detrimental to the cancer therapy.  
However, there is evidence that cancer cells still require functional mitochondria. 
Cancer cells with depleted mtDNA by growing in ethidium bromide show reduced 
growth rate, colony formation on soft agar and tumor formation in nude mice (Morais et 
al. 1994; Cavalli et al. 1997; Magda et al. 2008; Weinberg et al. 2010). Overexpression of 
oncogenic Myc has been observed in many aggressive tumors and found to upregulate 
mitochondrial respiration and biogenesis by the induction of TFAM and subunits of ETC 
complex I, uncoupling proteins, and mitochondrial membrane proteins (Li et al. 2005). 
Myc-mediated upregulation of mitochondrial function is also associated with induction of 
glutaminase, converting glutamine to glutamate, and glutamate is converted to ?-
ketoglutarate to enter the TCA cycle, rendering glutamine-dependent cancer cells with 
active mitochondrial function (Wise et al. 2008). Recently, reduced glycolysis and 
increased oxidative phosphorylation in certain melanomas has been reported (Haq et al. 
2013; Vazquez et al. 2013), indicating that not all cancer cells are inherently glycolytic, 
but rather have metabolic plasticity. Moreover, studies about the energy budget of various 
cancer cells under normoxic conditions demonstrate that most of the ATP in cancer cells 
still comes from mitochondrial oxidative phosphorylation, similar to normal cells (Zu and 
Guppy 2004). Consequently, inhibition of the mitochondrial function of MCL-1 may lead 
to effective cancer therapy. 
Different cancer cells may undergo different bioenergetics adjustments, either 
becoming more glycolytic or more oxidative, depending upon the tissue context, and 
stage of the cells during transformation. Therefore, targeting mitochondrial function of 
MCL-1 could give rise to different outcomes in cancer therapy and need further 
elucidation. 
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Potential Cardiac Complications of Targeting MCL-1 in Cancer Therapy 
Cancer treatments include chemotherapy, radiotherapy, surgical intervention and 
combination of different options. Many of these treatments have potential adverse side 
effect on cardiac function and would significantly affect the life quality, short-term and 
long-term survival of the patients. Common cardiac complications in cancer therapy 
include heart failure, myocardial ischemia, hypertension, thromboembolism, QT 
prolongation, and bradycardia. 
Several therapies for cancer have been associated with the development of left 
ventricle dysfunction and heart failure. The incidence of cardiac toxicity is determined by 
multiple factors, such as the cumulative dose, the administration schedule, and the use of 
other cardiotoxic treatments (Yeh and Bickford 2009). For example, anthracylcine (such 
as doxorubicin)-induced left ventricle dysfunction or heart failure occurs in 3% to 26% of 
patients (Von Hoff et al. 1979; Swain et al. 2003). Oxidative stress is the main 
explanation for antracycline-induced cardiotoxicity. Other mechanisms have also been 
postulated, such as induction of apoptosis, decreased ATP production by cardiomyocytes, 
downregulation of GPx acitivity, mitochondrial respiratory defects due to mtDNA 
damage, and topoisomerase II beta mediated DNA double-strand breaks (Wouters et al. 
2005; Lyu et al. 2007). The incidence of heart failure reported with tyrosine kinase 
inhibitor (such as bevacizumab, dasatanib, and imatinib) therapy ranges from 2% to 4%. 
The mechanisms of heart failure associated with tyrosine kinase inhibitors may be related 
to high blood pressure, inhibition of vascular endothelial growth factor (VEGF)/VEGF 
receptor signaling, and inhibition of c-Abl (Miller et al. 2005; Kerkela et al. 2006; Miller 
et al. 2007; Cella et al. 2011). In addition, ischemia and high blood pressure are common 
adverse effects occurring in patients treated with tyrosine kinase inhibitors (Yang et al. 
2003; Chu et al. 2007; Escudier et al. 2007; Procopio et al. 2007; Burstein et al. 2008). 
Therefore, cardiotoxicity related to cancer treatment is important to be recognized as it 
may affect the prognosis and survival of cancer patients. 
Importantly, our data demonstrate that MCL-1 is an essential regulator for cardiac 
homeostasis, via inhibiting cardiomyocyte death and promoting cardiac mitochondrial 
respiration. Our observation has important implication to human health, which suggests 
that a potential adverse side effect associated with pharmacological MCL-1 inhibition in 
cancer therapy might be cardiotoxicity.  Therefore, it is important to monitor the heart 
function of patients who are treated with MCL-1 inhibitors. Measuring systolic function 
through evaluation of left ventricle ejection fraction with ECHO is one of the most 
common measurements in monitoring and diagnosing chemotherapy-induced 
cardiomyopathy (Ganz et al. 1996). Endocardial biopsy is the gold standard for diagnosis, 
but the invasiveness of the procedure limits its use (Ganz et al. 1996). Moreover, 
biochemical markers, such as troponin and B-type natriuretic peptide can indicate 
myocardial injury before the changes in ejection fraction are apparent (Dao et al. 2001; 
Cardinale et al. 2002; Cardinale et al. 2004). To prevent the incidence of MCL-1 
inhibition-induced cardiotoxicity, clinicians may need to use cardio protectants, minimize 
patients’ lift-time does, as well as limit the use of other cardiotoxic treatments during 
cancer therapy. 
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CHAPTER 5.   FUTURE DIRECTIONS  
Contributions of Different MCL-1 Isoforms to Cardiac Function in vivo
Previous work from our laboratory has demonstrated that different forms of 
MCL-1 exhibit distinct submitochondrial localizations and possess separable functions 
(Perciavalle et al. 2012). On the OMM, full-length MCL-1 interacts with pro-apoptotic 
BCL-2 family proteins to antagonize cell death, whereas the N-terminal truncated MCL-1 
in the mitochondrial matrix promotes normal mitochondrial morphology and physiology 
(Perciavalle et al. 2012).  However, the biological relevance of those separable roles has 
not been revealed in vivo. Our data from the cardiac-specific Mcl-1-deleted mice indicate 
the possibility that both functions of MCL-1 are required for cardiac homeostasis.  
Therefore, it is necessary to functionally reconstitute Mcl-1-deleted heart with individual 
MCL-1 isoforms to determine the contributions of MCL-1’s anti-apoptotic function and 
its ability to promote mitochondrial physiology to cardiac homeostasis. 
Reconstitution of Mcl-1-deleted Hearts by Adeno-associated Virus Delivery 
Adeno-associated virus (AAV) is a small, noneveloped DNA virus that belongs to 
the parvovirus family, which is very popular in gene therapy as it is able to mediate stable 
and efficient gene expression (Michelfelder and Trepel 2009). To date, 12 AAV 
serotypes have been isolated from human or primate tissues (Michelfelder and Trepel 
2009), and different serotypes of AAV show various tissue preferences. Several studies 
have demonstrated that AAV serotype 8 (AAV8) is able to efficiently deliver genes to 
heart and muscle, and the expression can be sustained for months. Moreover, AAV8 
infection does not affect cardiac function (Wang et al. 2005; Zincarelli et al. 2008).  
To ensure AAV8-CMV is able to drive gene expression in the heart in our mouse 
model, newborn wild-type mice were injected with an AAV8-CMV construct expressing 
GFP (3×1011 genomic copy [g.c.] per pup) through the temporal vein. Robust and stable 
cardiac GFP expression was observed up to 20 wks post-injection by immunoblot 
(Figure 5-1A). AAV8 constructs expressing different isoforms of MCL-1 with an 
internal FLAG-epitope tag (FLINT) to differentiate them from endogenous protein were 
then given to neonatal mice and ECHO analysis during their adulthood revealed no 
deleterious effect on cardiac function, indicating that ectopic expression different forms 
of MCL-1 was tolerated (Figure 5-1B).  
The mutants used for MCL-1 reconstitution include Mcl-1Flint (protein localizes 
on both OMM and IMM and functions as wild-type MCL-1), CSFlint (protein localizes on 
the OMM and retains the anti-apoptotic activity) and MatrixFlint (protein localizes in the 
matrix and only promotes mitochondrial physiology). Postnatal day one (P1) Mcl-1flox/flox, 
Myh-Cre neonates were injected with different transgenic constructs (3×1011 g.c./pup) or 
vehicle (GFP) through the temporal vein. Tamoxifen was given six weeks after birth 
(injection). ECHO was initiated one week after tamoxifen induction for six weeks.  
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Figure 5-1. Delivery AAV constructs to the heart
(A) Immunoblot of GFP expression at indicated time points after treatment of wild-type 
mice with PBS (control) or AAV8-GFP. Samples were harvested at 4, 8, and 20 weeks 
after infection and blotted for GFP (AAV-encoded) or ATP5A1 (mitochondrial marker). 
(B) Ectopic expression of GFP or different forms of MCL-1 has no effect on cardiac 
function indicated by ejection fraction (EF) and fraction shortening (FS). Data are 
acquired six weeks after virus injection. The number of mice analyzed is indicated as (n). 
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Deletion of endogenous Mcl-1 in GFP-expressing mice led to a fatal, dilated 
cardiomyopathy (Figure 5-2), similar to what has been observed previously. In contrast, 
expression of ectopic MCL-1FLINT rescued the Mcl-1-deleted mice and improved their 
cardiac function (Figure 5-2). However, overexpression of either CSFLINT or MatrixFLINT
only partially rescued the survival, and the pathological and TEM analysis still 
demonstrated featured phenotypes analogue to Mcl-1-deleted heart (Figure 5-2). 
Interestingly, the onset of contractile dysfunction was different in mice expressing 
CSFLINT and MatrixFLINT. The contractility of CSFLINT overexpressed mice were quite 
stable till four weeks after tamoxifen initiation and decreased drastically thereafter, 
whereas the contractility of MatrixFLINT overexpressed mice started to decrease at the 
very beginning and the curves mostly overlap with GFP overexpressed mice. This 
observation indicates that anti-apoptotic function of MCL-1 is more critical for protecting 
cardiomyocytes against acute death while the mitochondrial function of MCL-1 is more 
important for keeping long-term cardiac health. Therefore, it is possible that both 
functions of MCL-1 are necessary for maintaining cardiac homeostasis. 
Although ectopic MCL-1FLINT rescued the survival and cardiac function of the 
Mcl-1-deleted mice, myofibril, connective tissue regeneration and mitochondrial damage 
can still be observed in the heart (Figure 5-2C, D). The possible explanation could be not 
all the Mcl-1-deleted cardiomyocytes are transduced by AAV, thus they cannot be 
rescued and still reveal the lesions.  
To resolve the caveat, we propose generating picornavirus 2A peptide-linked 
muticstronic AAV constructs to deliver both tamoxifen-inducible Cre and individual 
forms of MCL-1 to the heart. Besides the previously used mutants, we include two more 
transgenes: combination of MatrixFLINT and CSHIS (cleavage site mutant with a 
polyhistidine tag) functions as wild type MCL-1, and human BCL-w works as an anti-
apoptotic control (Figure 5-3).  The picornavirus 2A peptides function as cis-acting 
hydrolase elements, mediating the “cleavage” between two proteins via ribosomal 
skipping (de Felipe and Ryan 2004). The conventional approaches for co-expression of 
multiple proteins have several limitations, such as imbalanced protein expression and 
large size. In contrast, the small 2A peptide sequences allow for efficient and 
stoichiometric production of discrete proteins (Szymczak-Workman et al. 2012). To 
ensure the deletion of endogenous MCL-1 is cardiac specific, the cardiac-specific ?
myosin heavy chain (?-Mhc) promoter will be used instead of the ubiquitous CMV
promoter (Pacak et al. 2008). And it is necessary to validate whether the ?-Mhc
promoter-driven tamoxifen-inducible Cre is able to recapitulate the similar phenotypes 
observed in Mcl-1-deleted mice. If this is the case, after virus delivery and tamoxifen 
treatment, transduced cardiomyocytes should have their endogenous MCL-1 deleted and 
ectopic MCL-1 mutants overexpressed, alleviating the concern.  
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Figure 5-2. Normal cardiac function needs both isoforms of MCL-1
(A) Contractility of Mcl-1flox/flox Myh-CreER hearts overexpressed with GFP (control) or 
MCL-1 mutants . (*) P < 0.05. Error bars represent the standard error of the mean. Mice 
were injected with AAV virus at postnatal day 1 (P1) through the temporal vein and then 
treat with tamoxifen six weeks after injection. (B) H&E-stained cross sections of the 
heart indicate dilated cardiomyopathy and a loss of myofibrils. Fibrosis in the cross-
sections of the heart stained blue with the Masson's trichrome stain. (C) Transmission 
electron micrographs indicate disrupted myocardium and disorganized mitochondria with 
abnormal cristae structure in MCL-1 mutants overexpressed Mcl-1flox/flox, Myh-CreER
hearts after tamoxifen treatment. For the Mcl-1FLINT overexpressed samples, regions with 
relatively normal morphology are indicated by i and iii, whereas the regions with 
abnormal ultrastructure are indicated by ii and iv. Bars: top panels (lower magnification), 
2 ?m; bottom panels (higher magnification), 500 nm. (D) Survival of Mcl-1flox/flox, Myh-
CreER mice overexpressed with MCL-1 mutants after tamoxifen treatment. (E) The 
expression of MCL-1 mutants in the Mcl-1flox/flox, Myh-CreER hearts after AAV injection. 
Actin serves as the loading control. 
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Figure 5-3. Schematic illustration of 2A peptide-linked multicistronic cassettes 
MCL-1Flint localizes on both OMM and IMM and functions as wild-type MCL-1. CSFlint
localizes on the OMM and retain the anti-apoptotic ability. MatrixFlint localizes in the 
matrix and only promotes mitochondrial physiology. Combination of MatrixFLINT and 
CSHIS functions as wild type MCL-1. Human BCL-w works as an anti-apoptotic control. 
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Cardiac Function of TKO Mice under Stress 
Although inhibition of the intrinsic apoptotic pathway by genetic ablation of Bax 
and Bak significantly rescued the cardiac dysfunction due to Mcl-1 deletion, ckmm-TKO 
and tamoxifen-treated Myh-TKO mice still revealed defective myocardial organization 
and mitochondrial morphology under TEM. Furthermore, mitochondria isolated from 
Myh-TKO mice still exhibited impaired respiration and decreased mtDNA content. These 
data indicate that besides inhibiting apoptosis, MCL-1 is also necessary for maintaining 
cardiac mitochondrial function and important for long-term heart health and cardiac 
function under stress. 
Isoproterenol is a ?-adrenergic agonist and has positive inotropic and chronotropic 
effects on the heart, increasing the energy demands of the myocardium. Therefore, 
isoproterenol administration to the TKO mice may reveal more robust cardiac 
dysfunction since enhanced mitochondrial function is required in response to the drug. 
Myh-TKO mice were treated with tamoxifen for five days and followed by a low dose of 
isoproterenol (7.5 mg/kg body weight/day) for seven days (Nakai et al. 2007). The ECHO 
was performed one week after the initiation of isoproterenol (two weeks after tamoxifen 
initiation). In contrast to the prolonged survival and normal cardiac function observed in 
tamoxifen-treated Myh-TKO mice upto eight weeks after tamoxifen initiation, tamoxifen-
treated Myh-TKO mice challenged with isoproterenol exhibited death, dilated left 
ventricle and a significant contractile dysfunction only two weeks after tamoxifen 
initiation (Figure 5-4A, B, E). Histological analysis demonstrated loss of myofibrils and 
fibrosis (Figure 5-4C) and TEM analysis revealed severely damaged myocardium and 
mitochondrial cristae structure (Figure 5-4D), similar to observations in the Mcl-1-
deleted hearts. Further experiments are necessary to determine the mitochondrial 
respiration and mtDNA content of these hearts. No overt cardiac dysfunction or 
ultrastructural abnormalities is observed in the tamoxifen-treated Mcl-1wt/wt, Myh-Cre or 
Myh-DKO mice upon isoproterenol challenge (Figure 5-4).   
Therefore, even though cell death is inhibited by BAX and BAK loss, Mcl-1
deletion in the heart revealed cardiac dysfunction and ultrastructural damage in response 
to isoproterenol challenge, indicating that MCL-1’s function in promoting mitochondrial 
physiology and morphology is essential for normal cardiac function under stress. For 
further validation, we need to determine whether reconstitution of matrix-localized form 
of MCL-1 to the Myh-TKO hearts via AAV delivery could rescue the cardiac dysfunction 
upon isoproterenol treatment. If this is the case, both functions of MCL-1 are necessary 
for cardiac homeostasis (Figure 5-5). 
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Figure 5-4. Isoproterenol challenge induces cardiac dilation and contractile 
dysfunction in Myh-TKO heart
Mice were treated with tamoxifen for five days, and then isoproterenol for one week.   
(A) Transthoracic echocardiographic (ECHO) studies were performed one week after 
isoproterenol initiation. M-mode images were recorded through interventricular septum 
(IVS) and left ventrical posterior wall (LVPW) at the papillary muscle level to get the left 
ventricle (LV) dimensions and IVS and LVPW thickness. (B) Contractility of heart as 
measured by ECHO for left ventricular (LV) ejection fraction (EF) and fraction 
shortening (FS). * p<0.05, **p<0.01.  The number of mice analyzed is indicated as (n).
(C) H&E-stained cross sections of the heart indicate dilated cardiomyopathy and a loss of 
myofibrils. Fibrosis in the cross-sections of the heart stained blue with the Masson's 
trichrome stain. (D) Transmission electron micrographs indicate disrupted myocardium 
and disorganized mitochondria with abnormal cristae structure in Myh-TKO heart after 
tamoxifen and isoproterenol treatment. Bars: top panels (lower magnification), 2 ?m; 
bottom panels (higher magnification), 500 nm. (E) Survival of Mcl-1flox/flox, Myh-CreER , 
Myh-DKO, and Myh-TKO mice after tamoxifen and isoproterenol treatment. 
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Figure 5-5. MCL-1 is essential for cardiac homeostasis 
Both functions of MCL-1 are necessary for normal heart function. OMM-localized MCL-
1 inhibits cell death to promote cardiomyocytes survival, and matrix-localized MCL-1 
facilitates mitochondrial physiology and morphology to maintain cardiac function.  
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